Metabolic dysfunction‑associated steatotic liver disease: Pathogenesis, model and treatment (Review)

Ludwig J, Viggiano TR, McGill DB and Oh BJ: Nonalcoholic steatohepatitis: Mayo clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 55:434–438. 1980. View Article : Google Scholar : PubMed/NCBI

Dong W, Jiang H, Li Y, Lv L, Gong Y, Li B, Wang H and Zeng H: Interpretable machine learning analysis of immunoinflammatory biomarkers for predicting CHD among NAFLD patients. Cardiovasc Diabetol. 24:2632025. View Article : Google Scholar : PubMed/NCBI

Charu V, Liang JW, Mannalithara A, Kwong A, Tian L and Kim WR: Benchmarking clinical risk prediction algorithms with ensemble machine learning for the noninvasive diagnosis of liver fibrosis in NAFLD. Hepatology. 80:11842024. View Article : Google Scholar : PubMed/NCBI

Gawrieh S, Vilar-Gomez E, Wilson LA, Pike F, Kleiner DE, Neuschwander-Tetri BA, Diehl AM, Dasarathy S, Kowdley KV, Hameed B, et al: Increases and decreases in liver stiffness measurement are independently associated with the risk of liver-related events in NAFLD. J Hepatol. 81:600–608. 2024. View Article : Google Scholar : PubMed/NCBI

Marjot T: The endothelium as the gatekeeper of insulin's action on metabolic tissues: Implications for MASLD and MASH. J Hepatol. 83:808–810. 2025. View Article : Google Scholar : PubMed/NCBI

Nadeau KJ, Mayer-Davis EJ, Gubitosi-Klug R, Zeitler PS, Kahn SE and Dabelea D; SEARCH TODAY, RISE and DISCOVERY study groups: Youth-onset type 2 diabetes: What we've learned from key youth-onset type 2 diabetes studies, what we still don't know, and why it is important. Diabetes Care. 48:1136–1149. 2025. View Article : Google Scholar : PubMed/NCBI

The Lancet Gastroenterology Hepatology: Redefining non-alcoholic fatty liver disease: What's in a name? Lancet Gastroenterol Hepatol. 5:4192020. View Article : Google Scholar : PubMed/NCBI

Lazarus JV, Newsome PN, Francque SM, Kanwal F, Terrault NA and Rinella ME: Reply: A multi-society Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 79:E93–E94. 2024. View Article : Google Scholar

Zhang F, Zhang X, Lv B, Sun R, Zhao T and He N: Changes in epidemiology and treatment outcomes after the academic renaming from NAFLD to MAFLD/MASLD. Chin Hepatol. 7:900–903. 2025.In Chinese.

Bae JC: No More NAFLD: The term is now MASLD. Endocrinol Metab (Seoul). 39:92–94. 2024. View Article : Google Scholar : PubMed/NCBI

Drygalski K: Pharmacological treatment of MASLD: Contemporary treatment and future perspectives. Int J Mol Sci. 26:65182025. View Article : Google Scholar : PubMed/NCBI

Li H, Zhang Z, Jiang X, Li L, Hu T, Wang B and Deng Z: Meta-analysis and data mining of Chinese herbal medicines for the treatment of metabolic dysfunction-associated steatotic liver disease. Acad J Guangzhou Med Univ. 53:17–26. 2025.In Chinese.

Younossi ZM, Golabi P, Paik JM, Henry A, Dongen CV and Henry L: The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): A systematic review. Hepatology. 77:1335–1347. 2023. View Article : Google Scholar : PubMed/NCBI

Zhou F, Zhou J, Wang W, Zhang XJ, Ji YX, Zhang P, She ZG, Zhu L, Cai J and Li H: Unexpected rapid increase in the burden of NAFLD in China from 2008 to 2018: A systematic review and meta-analysis. Hepatology. 70:1119–1133. 2019. View Article : Google Scholar : PubMed/NCBI

Benedict M and Zhang X: Non-alcoholic fatty liver disease: An expanded review. World J Gastroenterol. 9:715–732. 2017.

Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L and Wymer M: Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 64:73–84. 2016. View Article : Google Scholar

Fang YL, Chen H, Wang CL and Liang L: Pathogenesis of non-alcoholic fatty liver disease in children and adolescence: from 'two hit theory' to 'multiple hit model'. World J Gastroenterol. 24:2974–2983. 2018. View Article : Google Scholar : PubMed/NCBI

Liu X and Gao H: Research progress of non-alcoholic fatty liver disease. J Hubei Univ Sci Technol (Med Sci). 33:364–368. 2019.In Chinese.

Tilg H and Moschen AR: Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis. Hepatology. 52:1836–1846. 2010. View Article : Google Scholar : PubMed/NCBI

Buzzetti E, Pinzani M and Tsochatzis EA: The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism. 65:1038–1048. 2016. View Article : Google Scholar : PubMed/NCBI

Mariana MV and Cortez-Pinto H: Non-alcoholic fatty liver disease: What the clinician needs to know. World J Gastroenterol. 20:12956–12980. 2014. View Article : Google Scholar

Fang C, Cai X, Hayashi S, Hao S, Sakiyama H, Wang X, Yang Q, Akira S, Nishiguchi S, Fujiwara N, et al: Caffeine-stimulated muscle IL-6 mediates alleviation of non-alcoholic fatty liver disease. Biochim Biophys Acta Mol Cell Biol Lipids. 1864:271–280. 2019. View Article : Google Scholar

Horton JD, Goldstein JL and Brown MS: SREBPs: Activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest. 109:1125–1131. 2002. View Article : Google Scholar : PubMed/NCBI

Thanapirom K and Tsochatzis EA: Non-alcoholic fatty liver disease (NAFLD) and the quest for effective treatments. Hepatobiliary Surg Nutr. 8:77–79. 2019. View Article : Google Scholar : PubMed/NCBI

Wilkinson AL, Qurashi M and Shetty S: The role of sinusoidal endothelial cells in the axis of inflammation and cancer within the liver. Front Physiol. 11:9902020. View Article : Google Scholar : PubMed/NCBI

Furuta K, Guo Q, Hirsova P and Ibrahim SH: Emerging roles of liver sinusoidal endothelial cells in nonalcoholic steatohepatitis. Biology (Basel). 9:3952020.PubMed/NCBI

Nasiri-Ansari N, Androutsakos T, Flessa CM, Kyrou I, Siasos G, Randeva HS, Kassi E and Papavassiliou AG: Endothelial cell dysfunction and nonalcoholic fatty liver disease (NAFLD): A concise review. Cells. 11:25112022. View Article : Google Scholar : PubMed/NCBI

Chen G, Cai X and Lu L: Role of hepatic sinusoidal endothelial cells in nonalcoholic steatohepatitis. Chin Hepatol. 29:998–1002. 2024.In Chinese.

Hammoutene A and Rautou PE: Role of liver sinusoidal endothelial cells in non-alcoholic fatty liver disease. Hepatology. 70:1278–1291. 2019. View Article : Google Scholar

Liu J, Ren CQ, Feng YL and He JR: Relationship between liver fibrosis and insulin resistance in patients with type 2 diabetes and nonalcoholic fatty liver disease. Chin J Clin Res. 34:443–448. 2021.In Chinese.

Wang Y, Xu D, Xu L and Wu Y: Peripheral blood TLR4, NF-κB mRNA in patients with type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease and their correlations with insulin resistance. Lab Med Clin. 19:925–929. 2022.In Chinese.

Dashti N, Williams DL and Alaupovic P: Effects of oleate and insulin on the production rates and cellular mRNA concentrations of apolipoproteins in HepG2 cells. J Lipid Res. 30:1365–1373. 1989. View Article : Google Scholar : PubMed/NCBI

Li X, Ni X and Hua J: Effect of hepatocyte fatty degeneration induced by free fatty acid on macrophage polarization. J Clin Hepatol. 37:385–389. 2021.In Chinese.

Zhang HB and Wang Y: Research progress of non-alcoholic fatty liver disease. Hainan Med J. 28:1651–1653. 2017.In Chinese.

Ye Y and Yu J: Adiponectin level, its gene polymorphism and nonalcoholic fatty liver disease. Basic Clin Med. 34:1285–1288. 2014.In Chinese.

Zou WS, Chen J and Zhang H: Expression and significance of osteopontin, leptin, visfatin and adiponectin in bile and gall-bladder mucosa. China J Mod Med. 29:30–35. 2019.In Chinese.

Shah SV and Fonseca VA: Iron and diabetes revisited. Diabetes Care. 34:1676–1677. 2011. View Article : Google Scholar : PubMed/NCBI

Zhan X: Research on the relationship between the iron metabolism parameters level and TCM syndrome types in nonalcoholic fatty liver disease. Fujian Univ Tradit Chin Med. 2020.In Chinese.

Nelson JE, Wilson L, Brunt EM, Yeh MM, Kleiner DE, Unalp-Arida A and Kowdley KV; Nonalcoholic Steatohepatitis Clinical Research Network: Relationship between the pattern of hepatic iron deposition and histological severity in nonalcoholic fatty liver disease. Hepatology. 53:448–457. 2011. View Article : Google Scholar : PubMed/NCBI

Baumeister SE, Völzke H, Marschall P, John U, Schmidt CO, Flessa S and Alte D: Impact of fatty liver disease on health care utilization and costs in a general population: A 5-year observation. Gastroenterology. 134:85–94. 2008. View Article : Google Scholar

Pagano C, Soardo G, Esposito W, Fallo F, Basan L, Donnini D, Federspil G, Sechi LA and Vettor R: Plasma adiponectin is decreased in nonalcoholic fatty liver disease. Eur J Endocrinol. 152:113–118. 2005. View Article : Google Scholar : PubMed/NCBI

Cohen ED and Fisher Edward A: Lipoprotein metabolism, dyslipidemia, and nonalcoholic fatty liver disease. Semin Liver Dis. 33:380–388. 2013. View Article : Google Scholar : PubMed/NCBI

Wang YY, Liang FX, Lu W, Song YJ, Ren JF, Zhou YD, Huang XX and Yang SR: Effects of electroacupuncture on insulin sensitivity and ediponectin/resistin gene expression in adipose tissue of obese insulin resistant rats. J Basic Chin Med. 27:1444–1450. 2021.In Chinese.

Xu MX, Wang M and Yang WW: Gold-quercetin nanoparticles prevent metabolic endotoxemia-induced kidney injury by regulating TLR4/NF-kappaB signaling and Nrf2 pathway in high fat diet fed mice. Int J Nanomedicine. 12:327–345. 2017. View Article : Google Scholar :

Mu H, Zhang Z, Liang C and Liu N: Study on the effect and its mechanism of carvedilol on leptin-induced activation and proliferation of human hepatic stellate cells. China Pharm. 28:2620–2624. 2017.In Chinese.

Begriche K, Massart J, Robin MA, Bonnet F and Fromenty B: Mitochondrial adaptations and dysfunctions in nonalcoholic fatty liver disease. Hepatology. 58:1497–1507. 2013. View Article : Google Scholar : PubMed/NCBI

Scott FL, Stec B, Pop C, Dobaczewska MK, Lee JJ, Monosov E, Robinson H, Salvesen GS, Schwarzenbacher R and Riedl SJ: The Fas-FADD death domain complex structure unravels signalling by receptor clustering. Nature. 457:1019–1022. 2009. View Article : Google Scholar : PubMed/NCBI

Arroyave-Ospina JC, Wu Z, Geng Y and Moshage H: Role of oxidative stress in the pathogenesis of non-alcoholic fatty liver disease: Implications for prevention and therapy. Antioxidants (Basel). 10:1742021. View Article : Google Scholar : PubMed/NCBI

Dong S, Liu P and Sun MY: Role of 'two-hit' in non-alcoholic fatty liver disease. J Clin Hepatol. 28:551–555. 2012.In Chinese.

Liu Y: Oxidative stress and hepatic protection. Chin J Gastroenterol Hepatol. 20:594–597. 2011.In Chinese.

Lamkanfi M, Sarkar A, Vande Walle L, Vitari AC, Amer AO, Wewers MD, Tracey KJ, Kanneganti TD and Dixit VM: Inflammasome-dependent release of the alarmin HMGB1 in endotoxemia. Immunology. 185:4385–4392. 2010.

Mridha AR, Haczeyni F, Yeh MM, Haigh WG, Ioannou GN, Barn V, Ajamieh H, Adams L, Hamdorf JM, Teoh NC and Farrell GC: TLR9 is up-regulated in human and murine NASH: Pivotal role in inflammatory recruitment and cell survival. Clin Sci (Lond). 131:2145–2159. 2017. View Article : Google Scholar : PubMed/NCBI

Sharifnia T, Antoun J, Verriere TG, Suarez G, Wattacheril J, Wilson KT, Peek RM Jr, Abumrad NN and Flynn CR: Hepatic TLR4 signaling in obese NAFLD. Am J Physiol Gastrointest Liver Physiol. 309:G270–G278. 2015. View Article : Google Scholar : PubMed/NCBI

Rocha DM, Caldas AP, Oliveira LL, Bressan J and Hermsdorff HH: Saturated fatty acids trigger TLR4-mediated inflammatory response. Atherosclerosis. 244:211–215. 2016. View Article : Google Scholar

Glass CK and Olefsky JM: Inflammation and lipid signaling in the etiology of insulin resistance. Cell Metab. 15:635–645. 2012. View Article : Google Scholar : PubMed/NCBI

Seimon TA, Nadolski MJ, Liao XH, Magallon J, Nguyen M, Feric NT, Koschinsky ML, Harkewicz R, Witztum JL, Tsimikas S, et al: Atherogenic lipids and lipo proteins trigger CD36-TLR2-dependent apoptosis in macrophages un dergoing endoplasmic reticulum stress. Cell Metab. 12:467–482. 2010. View Article : Google Scholar : PubMed/NCBI

Miura K and Ohnishi H: Role of gut microbiota and toll-like receptors in nonalcoholic fatty liver disease. World J Gastroenterol. 20:7381–7391. 2014. View Article : Google Scholar : PubMed/NCBI

Ashraf NU and Sheikh TA: Endoplasmic reticulum stress and oxidative stress in the pathogenesis of non-alcoholic fatty liver disease. Free Radic Res. 49:1405–1418. 2015. View Article : Google Scholar : PubMed/NCBI

Amir M and Czaja MJ: Autophagy in nonalcoholic steatohepatitis. Expert Rev Gastroenterol Hepatol. 5:159–166. 2011. View Article : Google Scholar : PubMed/NCBI

Gäbele E, Dostert K, Hofmann C, Wiest R, Schölmerich J, Hellerbrand C and Obermeier F: DSS induced colitis increases portal LPS levels and enhances hepatic inflammation and fibrogenesis in experimental NASH. Hepatology. 55:1391–1399. 2011. View Article : Google Scholar

Simonen P, Kotronen A, Hallikainen M, Sevastianova K, Makkonen J, Hakkarainen A, Lundbom N, Miettinen TA, Gylling H and Yki-Järvinen H: Cholesterol synthesis is increased and absorption decreased in non-alcoholic fatty liver disease independent of obesity. Hepatology. 54:153–159. 2011. View Article : Google Scholar

Enjoji M, Yasutake K, Kohjima M and Nakamuta M: Nutrition and nonalcoholic fatty liver disease: The significance of cholesterol. Int J Hepatol. 2012:9258072012. View Article : Google Scholar : PubMed/NCBI

Subramanian S, Goodspeed L, Wang S, Kim J, Zeng LX, Ioannou GN, Haigh WG, Yeh MM, Kowdley KV, O'Brien KD, et al: Dietary cholesterol exacerbates hepatic steatosis and inflammation in obese LDL receptor deficient mice. J Lipid Res. 52:1626–1635. 2011. View Article : Google Scholar : PubMed/NCBI

Ersoy BA, Maner-Smith KM, Li Y, Alpertunga I and Cohen DE: Thioesterase-mediated control of cellular calcium homeostasis enables hepatic ER stress. J Clin Invest. 128:141–156. 2018. View Article : Google Scholar :

Ghemrawi R, Battaglia-Hsu F and Arnold C: Endoplasmic reticulum stress in metabolic disorders. Cells. 7:632018. View Article : Google Scholar : PubMed/NCBI

Henkel AS: Unfolded protein response sensors in hepatic lipid metabolism and nonalcoholic fatty liver disease. Semin Liver Dis. 38:320–332. 2018. View Article : Google Scholar : PubMed/NCBI

DeZwaan-McCabe D, Sheldon RD, Gorecki MC, Guo DF, Gansemer ER, Kaufman RJ, Rahmouni K, Gillum MP, Taylor EB, Teesch LM and Rutkowski DT: ER Stress inhibits liver fatty acid oxidation while unmitigated stress leads to anorexia-induced lipolysis and both liver and kidney steatosis. Cell Rep. 19:1794–1806. 2017. View Article : Google Scholar : PubMed/NCBI

Maillo C, Martín J, Sebastián D, Hernández-Alvarez M, García-Rocha M, Reina O, Zorzano A, Fernandez M and Méndez R: Circadian- and UPR-dependent control of CPEB4 mediates a translational response to counteract hepatic steatosis under ER stress. Nat Cell Biol. 19:94–105. 2017. View Article : Google Scholar : PubMed/NCBI

Urano F, Wang X, Bertolotti A, Zhang Y, Chung P, Harding HP and Ron D: Coupling of stress in the ER to activation of JNK protein kinases by transmembrane protein kinase IRE1. Science. 287:664–666. 2000. View Article : Google Scholar : PubMed/NCBI

Li Y, Huang B, Jiang X, Chen W, Zhang J, Wei Y, Chen Y, Lian M, Bian Z, Miao Q, et al: Mucosal-associated invariant T cells improve nonalcoholic fatty liver disease through regulating macrophage polarization. Front Immunol. 9:19942018. View Article : Google Scholar : PubMed/NCBI

Ma J, Zhou Q and Li H: Gut Microbiota and nonalcoholic fatty liver disease: Insights on mechanisms and therapy. Nutrients. 9:11242017. View Article : Google Scholar : PubMed/NCBI

Harte AL, da Silva NF, Creely SJ, McGee KC, Billyard T, Youssef-Elabd EM, Tripathi G, Ashour E, Abdalla MS, Sharada HM, et al: Elevated endotoxin levels in non-alcoholic fatty liver disease. J Inflammation (Lond). 7:152010. View Article : Google Scholar

Ley RE, Turnbaugh PJ, Klein S and Gordon JI: Microbial ecology: Human gut microbes associated with obesity. Nature. 444:1022–1023. 2006. View Article : Google Scholar : PubMed/NCBI

Janssen AWF, Houben T, Katiraei S, Dijk W, Boutens L, van der Bolt N, Wang Z, Brown JM, Hazen SL, Mandard S, et al: Modulation of the gut microbiota impacts nonalcoholic fatty liver disease: A potential role for bile acids. J Lipid Res. 58:1399–1416. 2017. View Article : Google Scholar : PubMed/NCBI

Le Roy T, Llopis M, Lepage P, Bruneau A, Rabot S, Bevilacqua C, Martin P, Philippe C, Walker F, Bado A, et al: Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice. Gut. 62:1787–1794. 2013. View Article : Google Scholar

Hu H, Lin A, Kong M, Yao X, Yin M, Xia H, Ma J and Liu H: Intestinal microbiome and NAFLD: Molecular insights and therapeutic perspectives. World J Gastroenterol. 20:142–158. 2020. View Article : Google Scholar

Rennert C, Heil T, Schicht G, Stilkerich A, Seidemann L, Kegel-Hübner V, Seehofer D and Damm G: Prolonged lipid accumulation in cultured primary human hepatocytes rather leads to ER stress than oxidative stress. Int J Mol Sci. 21:70972020. View Article : Google Scholar : PubMed/NCBI

Wesolowski SR, Kasmi KC, Jonscher KR and Friedman JE: Developmental origins of NAFLD: A womb with a clue. Nat Rev Gastroenterol Hepatol. 14:81–96. 2017. View Article : Google Scholar :

Arab JP, Karpen SJ, Dawson PA, Arrese M and Trauner M: Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives. Hepatology. 65:350–362. 2017. View Article : Google Scholar

Jiang C, Xie C, Li F, Zhang L, Nichols RG, Krausz KW, Cai J, Qi Y, Fang ZZ, Takahashi S, et al: Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease. J Clin Invest. 125:386–402. 2015. View Article : Google Scholar :

Thomas C, Gioiello A, Noriega L, Strehle A, Oury J, Rizzo G, Macchiarulo A, Yamamoto H, Mataki C, Pruzanski M, et al: TGR5 mediated bile acid sensing controls glucose homeostasis. Cell Metab. 10:167–177. 2009. View Article : Google Scholar : PubMed/NCBI

Zhou T, Zheng Y, Liang H and Tang J: Progress of bile acid metabolism in chronic liver disease. J Integr Tradit Chin West Med Hepatol. 30:173–175. 2020.In Chinese.

Watanabe M, Houten SM, Mataki C, Christoffolete MA, Kim BW, Sato H, Messaddeq N, Harney JW, Ezaki O, Kodama T, et al: Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature. 439:484–489. 2006. View Article : Google Scholar : PubMed/NCBI

Wang F, Wang YY, Zhang D, Zhao XR and Liu K: Research on curative effects of regulating bile acid metabolism and intestinal flora in treatment of nonalcoholic fatty liver disease. China Med Pharm. 9:36–40. 452019.In Chinese.

Jiang LY and Xiao XH: Research progress on correlation between gut microbiota and non-alcoholic fatty liver disease. J Clin Pathol Res. 36:2060–2065. 2016.

Carr RM and Reid AE: FXR agonists as therapeutic agents for non-alcoholic fatty liver disease. Curr Atheroscler Rep. 17:5002015. View Article : Google Scholar : PubMed/NCBI

Liu K, Xu SY, Xu B, Chen D and Li N: The protective role of early autophagy in nonalcoholic fatty liver. Beijing Med J. 33:947–950. 2011.In Chinese.

Wang XL, Xiong JR, Zhao QM, Jiang W and Li P: The dual role of autophagy in disease. Prog Mod Biomed. 14:4997–5000. 2014.In Chinese.

Yang L, Li P, Fu S, Calay ES and Hotamisligil GS: Defective hepatic autophagy in obesity promotes ER stress and causes insulin resistance. Cell Metab. 11:467–478. 2010. View Article : Google Scholar : PubMed/NCBI

Ma DW, Ha J, Yoon KS, Kang I, Choi TG and Kim SS: Innate immune system in the pathogenesis of non-alcoholic fatty liver disease. Nutrients. 15:20682023. View Article : Google Scholar : PubMed/NCBI

Kazankov K, Jørgensen SMD, Thomsen KL, Møller HJ, Vilstrup H, George J, Schuppan D and Grønbæk H: The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Nat Rev Gastroenterol Hepatol. 16:145–159. 2019. View Article : Google Scholar

Tilg H, Effenberger M and Adolph TE: A role for il-1 inhibitors in the treatment of non-alcoholic fatty liver disease (NAFLD)? Expert Opin Investig Drugs. 29:1032020. View Article : Google Scholar

Hayden MS and Ghosh S: NF-κB, the first quarter-century: Remarkable progress and outstanding questions. Genes Dev. 26:203–234. 2012. View Article : Google Scholar : PubMed/NCBI

Garcia-Ruiz C, Mato JM, Vance D, Kaplowitz N and Fernández-Checa JC: Acid sphingomyelinase-ceramide system in steatohepatitis: A novel target regulating multiple pathways. J Hepatol. 62:2192015. View Article : Google Scholar

Fantuzzi G: Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol. 115:911–919; quiz 920. 2005. View Article : Google Scholar : PubMed/NCBI

Tong Q, Wang XL, Li SB, Yang GL, Jin S, Gao ZY and Liu XB: Combined detection of il-6 and il-8 is beneficial to the diagnosis of early-stage esophageal squamous cell cancer: A preliminary study based on the screening of serum markers using protein chips. OncoTargets Ther. 11:5777–5787. 2018. View Article : Google Scholar

Tikhomirova AS, Kislyakov VA, Baykova IE and Nikitin IG: Clinical-morphological parallels of the PNPLA3 gene polymorphism in patients with nonalcoholic fatty liver disease. Ter Arkh. 90:85–88. 2018.

Dai G, Liu P, Li X, Zhou X and He S: Association between PNPLA3 rs738409 polymorphism and nonalcoholic fatty liver disease (NAFLD) susceptibility and severity: a meta-analysis. Medicine (Baltimore). 98:e143242019. View Article : Google Scholar : PubMed/NCBI

Dongiovanni P, Petta S, Maglio C, Fracanzani AL, Pipitone R, Mozzi E, Motta BM, Kaminska D, Rametta R, Grimaudo S, et al: Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease. Hepatology. 61:506–514. 2015. View Article : Google Scholar

Wu S, Zheng B, Liu T, Zhu Z, Gu W and Liu Q: 17beta-hydroxysteroid dehydrogenase 3 deficiency due to novel compound heterozygous variants of HSD17B3 gene in a sib pair. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 38:787–790. 2021.In Chinese. PubMed/NCBI

Dai LL, Li SD, Ma YC, Tang JR, Lv JY, Zhang YQ, Miao YL, Ma YQ, Li CM, Chu YY, et al: MicroRNA-30b regulates insulin sensitivity by targeting SERCA2b in non-alcoholic fatty liver disease. Liver Int. 39:1504–1513. 2019. View Article : Google Scholar : PubMed/NCBI

Yu J, Peng J, Luan Z, Zheng F and Su W: MicroRNAs as a novel tool in the diagnosis of liver lipid dysregulation and fatty liver disease. Molecules. 24:2302019. View Article : Google Scholar : PubMed/NCBI

Dongiovanni P, Meroni M, Longo M, Fargion S and Fracanzani AL: miRNA signature in NAFLD: A turning point for a non-invasive diagnosis. Int J Mol Sci. 19:39662018. View Article : Google Scholar : PubMed/NCBI

Zhang M, Sun W, Zhou M and Tang Y: MicroRNA-27a regulates hepatic lipid metabolism and alleviates NAFLD via repressing FAS and SCD1. Sci Rep. 7:144932017. View Article : Google Scholar : PubMed/NCBI

Szabo G and Csak T: Role of microRNAs in NAFLD/NASH. Dig Dis Sci. 61:1314–1324. 2016. View Article : Google Scholar : PubMed/NCBI

López-Riera M, Conde I, Quintas G, Pedrola L, Zaragoza A, Perez-Rojas J, Salcedo M, Benlloch S, Castell JV and Jover R: Non-invasive prediction of NAFLD severity: A comprehensive, independent validation of previously postulated serum microRNA biomarkers. Sci Rep. 8:106062018. View Article : Google Scholar : PubMed/NCBI

Guo Y, Xiong Y, Sheng Q, Zhao S, Wattacheril J and Flynn CR: A micro-RNA expression signature for human NAFLD progression. J Gastroenterol. 51:1022–1030. 2016. View Article : Google Scholar : PubMed/NCBI

Luo ZL, Tang LJ, Wang T, Dai RW, Ren JD, Cheng L, Xiang K and Tian FZ: Effects of treatment with hydrogen sulfide on methionine-choline deficient diet-induced non-alcoholic steatohepatitis in rats. J Gastroenterol Hepatol. 29:215–222. 2014. View Article : Google Scholar

Wu D, Zheng N, Qi K, Cheng H, Sun Z, Gao B, Zhang Y, Pang W, Huangfu C, Ji S, et al: Exogenous hydrogen sulfide mitigates the fatty liver in obese mice through improving lipid metabolism and antioxidant potential. Med Gas Res. 5:12015. View Article : Google Scholar : PubMed/NCBI

Salehi-Sahlabadi A, Sadat S, Beigrezaei S, Pourmasomi M, Feizi A, Ghiasvand R, Hadi A, Clark CCT and Miraghajani M: Dietary patterns and risk of non-alcoholic fatty liver disease. BMC Gastroenterol. 21:412021. View Article : Google Scholar : PubMed/NCBI

Liu H and Ye H: Research progress on the relationship between sleep, circadian rhythm, intestinal flora and non-alcoholic fatty liver disease. Mod Pract Med. 31:565–568. 2019.In Chinese.

Wei YT, Lee PY, Lin CY, Chen HJ, Lin CC, Wu JS, Chang YF, Wu CL and Guo HR: Non-alcoholic fatty liver disease among patients with sleep disorders: A nationwide study of Taiwan. BMC Gastroenterol. 20:322020. View Article : Google Scholar : PubMed/NCBI

Marin-Alejandre BA, Abete I, Cantero I, Riezu-Boj JI, Milagro FI, Monreal JI, Elorz M, Herrero JI, Benito-Boillos A, Quiroga J, et al: Association between sleep disturbances and liver status in obese subjects with nonalcoholic fatty liver disease: A comparison with healthy controls. Nutrients. 11:3222019. View Article : Google Scholar : PubMed/NCBI

Ai Y, Yang X, Pan X and Ye J: Role of circadian clock genes in the development and progression of nonalcoholic fatty liver disease. J Clin Hepatol. 35:2327–2330. 2019.In Chinese.

Reinke H and Asher G: Circadian clock control of liver metabolic functions. Gastroenterology. 150:573–580. 2016. View Article : Google Scholar

Wen Y: Relationship between social mental factors and non-alcoholic fatty liver disease: A case-control study. China J Health Psychol. 26:565–568. 2018.In Chinese.

Cho IY, Chang Y, Sung E, Kang JH, Wild SH, Byrne CD, Shin H and Ryu S: Depression and increased risk of non-alcoholic fatty liver disease in individuals with obesity. Epidemiol Psychiatr Sci. 30:e232021. View Article : Google Scholar : PubMed/NCBI

Youssef NA, Abdelmalek MF, Binks M, Guy CD, Omenetti A, Smith AD, Diehl AM and Suzuki A: Associations of depression, anxiety and antidepressants with histological severity of nonalcoholic fatty liver disease. Liver Int. 33:1062–1070. 2013. View Article : Google Scholar : PubMed/NCBI

Peluso I, Manafikhi H, Reggi R and Palmery M: Effects of red wine on postprandial stress: Potential implication in non-alcoholic fatty liver disease development. Eur J Clin Nutr. 54:497–507. 2015. View Article : Google Scholar

Yu D, Shu XO, Xiang YB, Li H, Yang G, Gao YT, Zheng W and Zhang X: Higher dietary choline intake is associated with lower risk of nonalcoholic fatty liver in normal-weight Chinese women. J Nutr. 144:2034–2040. 2014. View Article : Google Scholar : PubMed/NCBI

Kado A, Inoue Y, Moriya M, Tsutsumi K, Ikeuchi T, Okushin K, Yotsuyanagi K, Koike H and Fujishiro M: Triglyceride level and soft drink consumption predict nonalcoholic fatty liver disease in nonobese male adolescents. Hepatol Res. 53:497–510. 2023. View Article : Google Scholar : PubMed/NCBI

Khazaei Y, Dehghanseresht N, Ebrahimi Mousavi S, Nazari M, Salamat S, Asbaghi O and Mansoori A: Association between protein intake from different animal and plant origins and the risk of non-alcoholic fatty liver disease: A case-control study. Clin Nutr Res. 12:29–39. 2023. View Article : Google Scholar : PubMed/NCBI

Lanaspa MA, Kuwabara M, Andres-Hernando A, Li N, Cicerchi C, Jensen T, Orlicky DJ, Roncal-Jimenez CA, Ishimoto T, Nakagawa T, et al: High salt intake causes leptin resistance and obesity in mice by stimulating endogenous fructose production and metabolism. Proc Natl Acad Sci USA. 115:3138–3143. 2018. View Article : Google Scholar : PubMed/NCBI

Liang YF, Kuang HY, Qin W, Zhu WB, Liu NJ, Zuo J and Han S: Correlation between salt intake and non-alcoholic fatty liver disease in type 2 diabetes mellitus patients in northern China. Chin J Mult Organ Dis Elderly. 18:765–768. 2019.In Chinese.

Chen S, Teoh NC, Chitturi S and Farrell GC: Coffee and non-alcoholic fatty liver disease: Brewing evidence for hepatoprotection? J Gastroenterol Hepatol. 29:435–441. 2014. View Article : Google Scholar

Sinha RA, Farah BL, Singh BK, Siddique MM, Li Y, Wu YJ, Ilkayeva OR, Gooding J, Ching J, Zhou J, et al: Caffeine stimulates hepatic lipid metabolism by the autophagy-lysosomal pathway in mice. Hepatology. 59:1366–1380. 2014. View Article : Google Scholar

Chen B, Sun L, Zeng G, Shen Z, Wang K, Yin L, Xu F, Wang P, Ding Y, Nie Q, et al: Gut bacteria alleviate smoking-related NASH by degrading gut nicotine. Nature. 610:562–568. 2022. View Article : Google Scholar : PubMed/NCBI

Jung HS, Chang Y, Kwon MJ, Sung E, Yun KE, Cho YK, Shin H and Ryu S: Smoking and the risk of non-alcoholic fatty liver disease: A cohort study. Am J Gastroenterol. 114:453–463. 2019. View Article : Google Scholar

Ma H, Zhao J and Xu J: The correlation between heavy metal ions in blood and metabolic dysfunction-associated steatotic liver disease from 1999 to 2018 based on NHANES data. Front Public Health. 12:15129012025. View Article : Google Scholar : PubMed/NCBI

Salman M, Kamel MA, El-Nabi SEH, Ismail AHA, Ullah S, Al-Ghamdi A, Hathout HMR and El-Garawani IM: The regulation of HBP1, SIRT1, and SREBP-1c genes and the related microRNAs in non-alcoholic fatty liver rats: The association with the folic acid anti-steatosis. PLoS One. 17:e02654552022. View Article : Google Scholar : PubMed/NCBI

Zhou Q, Xu W, Wang L and Duan Y: Polychlorinated biphenyl 118 induced nonalcoholic fatty liver disease in rats. J Nanjing Med Univ (Nat Sci). 39:659–663. 2019.In Chinese.

Stephen Robert JM, Peddha MS and Srivastava AK: Effect of silymarin and quercetin in a miniaturized scaffold in wistar rats against non-alcoholic fatty liver disease. ACS Omega. 6:20735–20745. 2021. View Article : Google Scholar : PubMed/NCBI

Zhang M, Yuan Y, Wang Q, Li X, Men J and Lin M: The Chinese medicine Chai Hu Li Zhong Tang protects against non-alcoholic fatty liver disease by activating AMPKα. Biosci Rep. 38:BSR201806442018. View Article : Google Scholar

Lin M, Deng G, Ou Y, Chen Z, Huang J, Kang M and Li J: Establishment of non-alcoholic fatty liver disease model in young rats induced by high-fat diet. J Med Theor Pract. 32:2321–2323. 23262019.In Chinese.

Jin Y, Xing W, Lyu A, Zhang J, Yang W, Xu Y, Wang Q and Li J: Comparison of CYP enzyme activities in rat models of nonalcoholic fatty liver established by different methods. Chin J Comp Med. 28:75–83. 2018.In Chinese.

Chen XQ, Xu LS, Li DF and Deng WP: Effects of glucagon-like peptide-1 analog on CDAA diet-induced models of nonalcoholic fatty liver fibrosis in rats. J Evid-Based Med. 17:163–170. 2017.In Chinese.

Yan D, Li SY and Wei YY: Study on establishment of animal model with diabetes complicated fatty liver induced by streptozocin and nicotinamide. Chin J Clin Pharmacol. 31:1846–1848. 2015.In Chinese.

Li X and Li Y: Discussion on nonalcoholic fatty liver disease animal model. Chin Community Doctors. 33:5–8. 2017.In Chinese.

Yong HY, Larrouy-Maumus G, Zloh M, Smyth R, Ataya R, Benton CM and Munday MR: Early detection of metabolic changes in drug-induced steatosis using metabolomics approache. RSC Adv. 10:41047–41057. 2020. View Article : Google Scholar : PubMed/NCBI

Che X and Han J: Effect of FGF21 on TLR4/p38MAPK signaling pathway in nonalcoholic fatty liver diseases of rats. J Med Res. 47:130–135. 2018.In Chinese.

Hakkak R, Spray B, Børsheim E and Korourian S: Diet containing soy protein concentrate with low and high isoflavones for 9 weeks protects against non-alcoholic fatty liver steatosis using obese zucker rats. Front Nutr. 9:9135712022. View Article : Google Scholar : PubMed/NCBI

Matsumoto Y, Fujita S, Yamagishi A, Shirai T, Maeda Y, Suzuki T, Kobayashi KI, Inoue J and Yamamoto Y: Brown rice inhibits development of nonalcoholic fatty liver disease in obese zucker (fa/fa) rats by increasing lipid oxidation via activation of retinoic acid synthesis. J Nutr. 151:2705–2713. 2021. View Article : Google Scholar : PubMed/NCBI

Xia QS, Gao Y, Wen-Bin W, Wu F, Dong H, Xu LJ, Fang K, Hu ML, Yuan F, Lu FE and Gong J: Ban-xia-xie-xin-tang ameliorates hepatic steatosis by regulating cidea and cidec expression in HFD-fed mice. Phytomedicine. 105:1543512022. View Article : Google Scholar : PubMed/NCBI

Shi Y, Laba PC, Zhang DY, Weng SQ, Liu XY and Wang HQ: Effects of bifidobacteria on high-fat diet-induced non-alcoholic fatty liver disease in C57BL/6 mice. Chin J Clin Med. 29:473–480. 2022.In Chinese.

Yu H, Yi X, Gao X, Ji J, Liu Z, Xia G, Li C, Zhang X and Shen X: Tilapia-head chondroitin sulfate protects against nonalcoholic fatty liver disease via modulating the gut-liver axis in High-Fat-Diet-Fed C57BL/6 mice. Foods. 11:9222022. View Article : Google Scholar : PubMed/NCBI

De Minicis S, Agostinelli L, Rychlicki C, Sorice GP, Saccomanno S, Candelaresi C, Giaccari A, Trozzi L, Pierantonelli I, Mingarelli E, et al: HCC development is associated to peripheral insulin resistance in a mouse model of NASH. PLoS One. 9:e00971362014. View Article : Google Scholar

Li XC, Zhang XY, Xu S, Li H and Zhang YH: Establishment of a non-alcoholic fatty liver model in C57BL/6J mice. In: Proceedings of the Symposium on Veterinary Toxicology and Feed Toxicology and the 4th National Congress of the Veterinary Toxicology Committee of the Chinese Society of Toxicology; Beijing. pp. 94–95. 2013, In Chinese.

Feng Z, Pang L, Chen S, Wei J, Huang Q, Wang Y and Lin X: The protective effect of Melissa officinalis on dexamethasone-induced nonalcoholic fatty liver in C57BL/6J mice. J Chin Med Mater. 44:961–965. 2021.In Chinese.

Asgharpour A, Cazanave SC, Pacana T, Seneshaw M, Vincent R, Banini BA, Kumar DP, Daita K, Min HK, Mirshahi F, et al: A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer. J Hepatol. 65:579–588. 2016. View Article : Google Scholar : PubMed/NCBI

Ma H, Zhu G, Zhang X, Yang R, Xie Y, Liu X and Wang B: An establishment method of a mouse model of non-alcoholic fatty liver disease. J Anhui Agric Sci. 49:80–84. 2021.In Chinese.

Jahn D, Dorbath D, Kircher S, Nier A, Bergheim I, Lenaerts K, Hermanns HM and Geier A: Beneficial effects of vitamin d treatment in an obese mouse model of non-alcoholic steatohepatitis. Nutrients. 11:772019. View Article : Google Scholar : PubMed/NCBI

Wang JJ, Fang HL, Li CW, Chen FC, Tang WJ, Jiang XY, Wu HY and Chen DL: Establishment of non-alcoholic fatty liver model in mice. J Clin Rehabilit Tissue Eng Res. 15:4395–4399. 2011.In Chinese.

Liu T, Tan F, Long X, Pan Y, Mu J, Zhou X, Yi R and Zhao X: Improvement effect of lotus leaf flavonoids on carbon tetrachloride-induced liver injury in mice. Biomedicines. 8:412020. View Article : Google Scholar : PubMed/NCBI

Malloy VL, Perrone CE, Mattocks DA, Ables GP, Caliendo NS, Orentreich DS and Orentreich N: Methionine restriction prevents the progression of hepatic steatosis in leptin-deficient obese mice. Metabolism. 62:1651–1661. 2013. View Article : Google Scholar : PubMed/NCBI

Son YJ, Jung DS, Shin JM, Kim M, Yoo G and Nho CW: Yellow loosestrife (lysimachia vulgaris var. davurica) ameliorates liver fibrosis in db/db mice with methionine and choline-deficient diet-induced nonalcoholic steatohepatitis. BMC Complement Med and Ther. 21:442021. View Article : Google Scholar

Yu W, Zhang J, Liu Y, Liu F, Shao H and Han G: Improvement effect of mussel polysaccharide α-d-glucan on non-alcoholic fatty liver apolipoprotein E knockout mice induced by high fat diet. Sci Technol Food Ind. 43:369–376. 2022.In Chinese.

Song L, Tang SQ, Tong JW, Cai P, Liu JX, Ren XJ and Huang W: Study on the mechanism of Xuefu Zhuyu decoction in preventing and treating NAFLD. Chin J Integr Tradit West Med. 40:1103–1106. 2020.In Chinese.

Yang P, Wang Y, Tang W, Sun W, Ma Y, Lin S, Jing J, Jiang L, Shi H, Song Z and Yu L: Western diet induces severe nonalcoholic steatohepatitis, ductular reaction, and hepatic fibrosis in liver CGI-58 knockout mice. Sci Rep. 10:47012020. View Article : Google Scholar : PubMed/NCBI

Piguet AC, Saran U, Simillion C, Keller I, Terracciano L, Reeves HL and Dufour JF: Regular exercise decreases liver tumors development in hepatocyte-specific PTEN-deficient mice independently of steatosis. J Hepatol. 62:1296–1303. 2015. View Article : Google Scholar : PubMed/NCBI

Semba T, Nishimura M, Nishimura S, Ohara O, Ishige T, Ohno S, Nonaka K, Sogawa K, Satoh M, Sawai S, et al: The FLS (fatty liver Shionogi) mouse reveals local expressions of lipocalin-2, CXCL1 and CXCL9 in the liver with non-alcoholic steatohepatitis. BMC Gastroenterol. 13:1202013. View Article : Google Scholar : PubMed/NCBI

Li JZ, Huang Y, Karaman R, Ivanova PT, Brown HA, Roddy T, Castro-Perez J, Cohen JC and Hobbs HH: Chronic overexpression of PNPLA3I148M in mouse liver causes hepatic steatosis. J Clin Invest. 122:4130–4144. 2012. View Article : Google Scholar : PubMed/NCBI

Yin HQ, Kim M, Kim JH, Kong G, Lee MO, Kang KS, Yoon BI, Kim HL and Lee BH: Hepatic gene expression profiling and lipid homeostasis in mice exposed to steatogenic drug, tetracycline. Toxicol Sci. 94:206–216. 2006. View Article : Google Scholar : PubMed/NCBI

Li Z, Jin H, Oh SY and Ji GE: Anti-obese effects of two lactobacilli and two bifidobacteria on ICR mice fed on a high fat diet. Biochem Biophys Res Commun. 480:222–227. 2016. View Article : Google Scholar : PubMed/NCBI

Yu Z, He Y, Luo W and Li L: Establishment of AKT gene-mediated non-alcoholic fatty liver models in mice. Acta Med Univ Sci Technol Huazhong. 45:170–175. 2016.In Chinese.

López-Lemus UA, Garza-Guajardo R, Barboza-Quintana O, Rodríguez-Hernandez A, García-Rivera A, Madrigal-Pérez VM, Guzmán-Esquivel J, García-Labastida LE, Soriano-Hernández AD, Martínez-Fierro ML, et al: Association between nonalcoholic fatty liver disease and severe male reproductive organ impairment (germinal epithelial loss): study on a mouse model and on human patients. Am J Mens Health. 12:639–648. 2018. View Article : Google Scholar : PubMed/NCBI

Musolino V, Gliozzi M, Scarano F, Bosco F, Scicchitano M, Nucera S, Carresi C, Ruga S, Zito MC, Maiuolo J, et al: Bergamot polyphenols improve dyslipidemia and pathophysiological features in a mouse model of non-alcoholic fatty liver disease. Sci Rep. 10:25652020. View Article : Google Scholar : PubMed/NCBI

Chow JD, Jones ME, Prelle K, Simpson ER and Boon WC: A selective estrogen receptor α agonist ameliorates hepatic steatosis in the male aromatase knockout mouse. J Endocrinol. 210:323–334. 2011. View Article : Google Scholar : PubMed/NCBI

Komatsu G, Nonomura T, Sasaki M, Ishida Y, Arai S and Miyazaki T: AIM-deficient mouse fed a high-trans-fat, high-cholesterol diet: A new animal model for nonalcoholic fatty liver disease. Exp Anim. 68:147–158. 2019. View Article : Google Scholar

Nguyen TTP, Kim DY, Lee YG, Lee YS, Truong XT, Lee JH, Song DK, Kwon TK, Park SH, Jung CH, et al: SREBP-1c impairs ULK1 sulfhydration-mediated autophagic flux to promote hepatic steatosis in high-fat-diet-fed mice. Mol Cell. 81:3820–3832.e7. 2021. View Article : Google Scholar : PubMed/NCBI

Deguise MO, Pileggi C, De Repentigny Y, Beauvais A, Tierney A, Chehade L, Michaud J, Llavero-Hurtado M, Lamont D, Atrih A, et al: SMN depleted mice offer a robust and rapid onset model of nonalcoholic fatty liver disease. Cell Mol Gastroenterol Hepatol. 12:354–377.e3. 2021. View Article : Google Scholar : PubMed/NCBI

Cano A, Buque X, Martínez-Uña M, Aurrekoetxea I, Menor A, García-Rodríguez JL, Lu SC, Martínez-Chantar ML, Mato JM, Ochoa B and Aspichueta P: Methionine adenosyltransferase 1A gene deletion disrupts hepatic very low-density lipoprotein assembly in mice. Hepatology. 54:1975–1986. 2011. View Article : Google Scholar : PubMed/NCBI

Heintz MM, Kumar R, Rutledge MM and Baldwin WS: Cyp2b-nullmale mice are susceptible to diet-induced obesity and perturbations in lipid homeostasis. J Nutr Biochem. 70:125–137. 2019. View Article : Google Scholar : PubMed/NCBI

Edmunds LR, Xie B, Mills AM, Huckestein BR, Undamatla R, Murali A, Pangburn MM, Martin J, Sipula I, Kaufman BA, et al: Liver-specific Prkn knockout mice are more susceptible to diet-induced hepatic steatosis and insulin resistance. Mol Metab. 41:1010512020. View Article : Google Scholar : PubMed/NCBI

Yang W, Yan X, Chen R, Xin X, Ge S, Zhao Y, Yan X and Zhang J: Smad4 deficiency in hepatocytes attenuates NAFLD progression via inhibition of lipogenesis and macrophage polarization. Cell Death Dis. 16:582025. View Article : Google Scholar : PubMed/NCBI

Yang YQ, Feng J, Bai X, Shen ZM, Liu XW, Gao J, Xie JY, Hu JH and Gao C: Establishment of a Microtus fortis model of non-alcoholic fatty liver. Acta Lab Anim Sci Sin. 21:34–38. 2013.In Chinese.

Yu Z, Wang H, Gao G, Ke L, Zhou J, Rao P and Yu C: Effects of freshwater clam soup nanoparticles on non-alcoholic fatty liver disease of Meriones unguieulataus. J Chin Inst Food Sci Technol. 21:116–120. 2021.In Chinese.

Bhathena J, Kulamarva A, Martoni C, Urbanska AM, Malhotra M, Paul A and Prakash S: Diet-induced metabolic hamster model of nonalcoholic fatty liver disease. Diabetes Metab Syndr Obes. 4:195–203. 2011.PubMed/NCBI

Cui CX, Deng JN, Li Y, Liu YY, Fan JY, Mu HN, Sun HY, Wang YH and Han JY: Silibinin capsules improves high fat diet-induced nonalcoholic fatty liver disease in hamsters through modifying hepatic de novo lipogenesis and fatty acid oxidation. J Ethnopharmacol. 208:24–35. 2017. View Article : Google Scholar : PubMed/NCBI

Zhao CZ, Jiang W, Zhu YY, Wang CZ, Zhong WH, Wu G, Chen J, Zhu MN, Wu QL, Du XL, et al: Highland barley monascus purpureus went extract ameliorates high-fat, high-fructose, high-cholesterol diet induced nonalcoholic fatty liver disease by regulating lipid metabolism in golden hamsters. J Ethnopharmacol. 286:1149222022. View Article : Google Scholar

Skat-Rørdam J, Pedersen K, Skovsted GF, Gregersen I, Vangsgaard S, Ipsen DH, Latta M, Lykkesfeldt J and Tveden-Nyborg P: Vitamin C deficiency may delay diet-induced NASH regression in the guinea pig. Antioxidants (Basel). 11:692021. View Article : Google Scholar

Jin M, Zheng L, Wei Y, Cheng J, Zhang D, Yan S, Qin H, Wang Q, Ci X and Feng H: Enterobacter cloacae aggravates metabolic disease by inducing inflammation and lipid accumulation. Environ Toxicol Pharmacol. 90:1038192022. View Article : Google Scholar : PubMed/NCBI

Ipsen DH, SkatRørdam J, Tsamouri MM, Latta M, Lykkesfeldt J and TvedenNyborg P: Molecular drivers of non-alcoholic steatohepatitis are sustained in mild-to-late fibrosis progression in a guinea pig model. Mol Genet Genomics. 294:649–661. 2019. View Article : Google Scholar : PubMed/NCBI

Pedersen K, Ipsen DH, Skat-Rrdam J, Lykkesfeldt J and Tveden-Nyborg P: Dietary long-chain fatty acids accelerate metabolic dysfunction in guinea pigs with non-alcoholic steatohepatitis. Nutrients. 15:24452023. View Article : Google Scholar : PubMed/NCBI

Wang Y, Zhang P, Su X, Yu Q, Chen Y, Guan H, Liu E and Fan J: Establishment of a novel nonalcoholic fatty liver disease model using cholesterol-fed rabbits with reference to the potential role of endoplasmic reticulum stress. Mol Med Rep. 18:2898–2904. 2018.PubMed/NCBI

Sturzeneker MCS, de Noronha L, Olandoski M, Wendling LU and Precoma DB: Ramipril significantly attenuates the development of non-alcoholic steatohepatitis in hyperlipidaemic rabbits. Am J Cardiovasc Dis. 9:8–17. 2019.PubMed/NCBI

Nguyen TN, Podkowa AS, Tam AY, Arnold EC, Miller RJ, Park TH, Do MN and Oelze ML: Characterizing fatty liver in vivo in rabbits, using quantitative ultrasound. Ultrasound Med Biol. 45:2049–2062. 2019. View Article : Google Scholar : PubMed/NCBI

Zheng W, Liu YL, Shang HB, Zhang Y, Ma DW, Hou N, Wang J, Sun XT, Peng Y, Pan L, et al: Characterization of spontaneously-developed non-alcoholic fatty liver disease in aged rhesus monkeys. Diabetol Metab Syndr. 10:682018. View Article : Google Scholar : PubMed/NCBI

Cydylo MA, Davis AT and Kavanagh K: Fatty liver promotes fibrosis in monkeys consuming high fructose. Obesity (Silver Spring). 25:290–293. 2017. View Article : Google Scholar : PubMed/NCBI

Kramer JA, Grindley J, Crowell AM, Makaron L, Kohli R, Kirby M, Mansfield KG and Wachtman LM: The common marmoset as a model for the study of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Vet Pathol. 52:404–413. 2015. View Article : Google Scholar

Hamid H, Zhang JY, Li WX, Liu C, Li ML, Zhao LH, Ji C and Ma QG: Interactions between the cecal microbiota and non-alcoholic steatohepatitis using laying hens as the model. Poult Sci. 98:2509–2521. 2019. View Article : Google Scholar : PubMed/NCBI

Zhu L, Liao R, Huang J, Yan H, Xiao C, Yang Y, Wang H and Yang C: The miR-216/miR-217 Cluster regulates lipid metabolism in laying hens with fatty liver syndrome via PPAR/SREBP signaling pathway. Front Vet Sci. 9:9138412022. View Article : Google Scholar : PubMed/NCBI

Tian WH, Wang Z, Yue YX, Li H, Li ZJ, Han RL, Tian YD, Kang XT and Liu XJ: Mir-34a-5p increases hepatic triglycerides and total cholesterol levels by regulating acsl1 protein expression in laying hens. Int J Mol Sci. 20:44202019. View Article : Google Scholar : PubMed/NCBI

Song J, Shi X, Li X, Liang Q, Zeng L, Li G, Yan Y, Xu G and Zheng J: Associations of the T329S polymorphism in flavin-containing monooxygenase 3 with atherosclerosis and fatty liver syndrome in 90-week-old hens. Front Vet Sci. 9:8686022022. View Article : Google Scholar : PubMed/NCBI

Delgado ME, Cárdenas BI, Farran N and Fernandez M: Metabolic reprogramming of liver fibrosis. Cells. 10:36042021. View Article : Google Scholar : PubMed/NCBI

Mazza G, Al-Akkad W and Rombouts K: Engineering in vitro models of hepatofibrogenesis. Adv Drug Deliv Rev. 121:147–157. 2017. View Article : Google Scholar : PubMed/NCBI

Soret PA, Magusto J, Housset C and Gautheron J: In vitro and in vivo models of non-alcoholic fatty liver disease: A critical appraisal. J Clin Med. 10:362020. View Article : Google Scholar : PubMed/NCBI

Zhong Y, Yu JS, Wang X, Binas B and Yoo HH: Chemical-based primary human hepatocyte monolayer culture for the study of drug metabolism and hepato-toxicity: comparison with the spheroid model. FASEB J. 35:e213792021. View Article : Google Scholar

Kanasaki A, Iida T, Murao K, Shirouchi B and Sato M: D-Allulose enhances uptake of HDL-cholesterol into rat's primary hepatocyte via SR-B1. Cytotechnology. 72:295–301. 2020. View Article : Google Scholar : PubMed/NCBI

Ng IC, Zhang L, Shen NNYY, Soong YT, Ng CW, Koh PKS, Zhou Y and Yu H: Isolation of primary rat hepatocytes with multiparameter perfusion control. J Vis Exp. e622892021.

Xie Y, Yao J, Jin W, Ren L and Li X: Induction and maturation of hepatocyte-like cells in vitro: Focus on technological advances and challenges. Front Cell Dev Biol. 9:7659802021. View Article : Google Scholar : PubMed/NCBI

Oseini AM, Cole BK, Issa D, Feaver RE and Sanyal AJ: Translating scientific discovery: The need for preclinical models of nonalcoholic steatohepatitis. Hepatol Int. 12:6–16. 2018. View Article : Google Scholar : PubMed/NCBI

Zhao S, Rong C, Zhang S, Liu Y and Chen J: Protective effects of polysaccharides of Auricularia auricula polysaccharide on ethanol-induced liver injury. Jiangsu Agric Sci. 45:142–144. 2017.In Chinese.

Yu QQ, Meng MR, Liu YY, Cheng YX and Chen Y: Preventive effect and underlying mechanism of dihydrocumin on NAFLD in oleic acid-treated HepG2 cells. Chin Tradit Herb Drugs. 49:1092–1099. 2018.In Chinese.

Mann DA: Human induced pluripotent stem cell-derived hepatocytes for toxicology testing. Expert Opin Drug Metab Toxicol. 11:1–5. 2015. View Article : Google Scholar

Chen Y and Ma K: NLRC4 inflammasome activation regulated by TNF-α promotes inflammatory responses in nonalcoholic fatty liver disease. Biochem Biophys Res Commun. 511:524–530. 2019. View Article : Google Scholar : PubMed/NCBI

Giraudi PJ, Becerra VJB, Marina V, Chavez-Tapiaa NC, Tiribelli C and Rosso N: The importance of the interaction between hepatocyte and hepatic stellate cells in fibrogenesis induced by fatty accumulation. Exp Mol Pathol. 98:85–92. 2015. View Article : Google Scholar

Feaver RE, Cole BK, Lawson MJ, Hoang SA, Marukian S, Blackman BR, Figler RA, Sanyal AJ, Wamhoff BR and Dash A: Development of an in vitro human liver system for interrogating nonalcoholic steatohepatitis. JCI Insight. 1:e909542016. View Article : Google Scholar : PubMed/NCBI

Salerno S, Campana C, Morelli S, Drioli E and De Bartolo L: Human hepatocytes and endothelial cells in organotypic membrane systems. Biomaterials. 32:8848–8859. 2011. View Article : Google Scholar : PubMed/NCBI

Ebrahimkhani MR, Neiman JA, Raredon MS, Hughes DJ and Griffith LG: Bioreactor technologies to support liver function in vitro. Adv Drug Deliv Rev. 69:132–157. 2014. View Article : Google Scholar : PubMed/NCBI

Kamei KI, Yoshioka M, Terada S, Tokunaga Y and Chen Y: Three-dimensional cultured liver-on-a-Chip with mature hepatocyte-like cells derived from human pluripotent stem cells. Biomed Microdevices. 21:732019. View Article : Google Scholar : PubMed/NCBI

Kostrzewski T, Maraver P, Ouro-Gnao L, Levi A, Snow S, Miedzik A, Rombouts K and Hughes D: A microphysiological system for studying nonalcoholic steatohepatitis. Hepatol Commun. 4:77–91. 2020. View Article : Google Scholar : PubMed/NCBI

Kostrzewski T, Cornforth T, Snow SA, Ouro-Gnao L, Rowe C, Large EM and Hughes DJ: Three-dimensional perfused human in vitro model of non-alcoholic fatty liver disease. World J Gastroenterol. 23:204–215. 2017. View Article : Google Scholar : PubMed/NCBI

Gaskell H, Sharma P, Colley HE, Murdoch C, Williams DP and Webb SD: Characterization of a functional C3A liver spheroid model. Toxicol Res (Camb). 5:1053–1065. 2016. View Article : Google Scholar : PubMed/NCBI

Rose S, Ezan F, Cuvellier M, Bruyère A, Legagneux V, Langouët S and Baffet G: Generation of proliferating human adult hepatocytes using optimized 3D culture conditions. Sci Rep. 11:5152021. View Article : Google Scholar : PubMed/NCBI

Vorrink SU, Zhou Y, Ingelman-Sundberg M and Lauschke VM: Prediction of drug-induced hepatotoxicity using long-term stable primary hepatic 3D spheroid cultures in chemically defined conditions. Toxicol Sci. 163:655–665. 2018. View Article : Google Scholar : PubMed/NCBI

Messner S, Fredriksson L, Lauschke VM, Roessger K, Escher C, Bober M, Kelm JM, Ingelman-Sundberg M and Moritz W: Transcriptomic, proteomic, and functional long-term characterization of multicellular three-dimensional human liver microtissues. Appl In Vitro Toxicol. 4:1–12. 2018. View Article : Google Scholar : PubMed/NCBI

Rubiano A, Indapurkar A, Yokosawa R, Miedzik A, Rosenzweig B, Arefin A, Moulin CM, Dame K, Hartman N, Volpe DA, et al: Characterizing the reproducibility in using a liver microphysiological system for assaying drug toxicity, metabolism, and accumulation. Clin Transl Sci. 14:1049–1061. 2021. View Article : Google Scholar : PubMed/NCBI

Hu H, Gehart H, Artegiani B, López-Iglesias C, Dekkers F, Basak O, van Es J, Chuva de Sousa Lopes SM, Begthel H, Korving J, et al: Long-term expansion of functional mouse and human hepatocytes as 3D organoids. Cell. 175:1591–1606. e192018. View Article : Google Scholar : PubMed/NCBI

Guan Y, Xu D, Garfin PM, Ehmer U, Hurwitz M, Enns G, Michie S, Wu M, Zheng M, Nishimura T, et al: Human hepatic organoids for the analysis of human genetic diseases. J Clin Invest Insight. 2:e949542017.

Wang Y, Wang H, Deng P, Tao T, Liu H and Wu S, Chen W and Wu S: Modeling human nonalcoholic fatty liver disease (NAFLD) with an organoids-on-a-chip system. ACS Biomater Sci Eng. 6:5734–5743. 2020. View Article : Google Scholar : PubMed/NCBI

Fernandes R, Luo X, Tsao CY, Payne GF, Ghodssi R, Rubloffde GW and Bentley WE: Biological nanofactories facilitate spatially selective capture and manipulation of quorum sensing bacteria in a bioMEMS device. Lab Chip. 10:1128–1134. 2010. View Article : Google Scholar : PubMed/NCBI

Kang D, Hong G, An S, Jang I, Yun WS, Shim JH and Jin S: Bioprinting of multiscaled hepatic lobules within a highly vascularized construct. Small. 16:e19055052020. View Article : Google Scholar : PubMed/NCBI

Mazzocchi A, Devarasetty M, Huntwork R, Soker S and Skardal A: Optimization of collagen type I-hyaluronan hybrid bioink for 3D bioprinted liver microenvironments. Biofabrication. 11:0150032018. View Article : Google Scholar : PubMed/NCBI

Do A, Zahrawi F and Mehal WZ: Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH). Nat Rev Drug Discov. 24:171–189. 2025. View Article : Google Scholar

Dai Q, Ain Q, Seth N, Rooney M and Zipprich A: Liver sinusoidal endothelial cells: Friend or foe in metabolic dysfunction-associated steatotic liver disease/metabolic dysfunction-associated steatohepatitis. Dig Liver Dis. 57:493–503. 2025. View Article : Google Scholar : PubMed/NCBI

Kuchay MS, Choudhary NS and Ramos-Molina B: Pathophysiological underpinnings of metabolic dysfunction-associated steatotic liver disease. Am J Physiol Cell Physiol. 328:C1637–C1666. 2025. View Article : Google Scholar : PubMed/NCBI

Sun HS, Nie CC, Li P, Liu Y and Gao L: Pharmacological treatment of non-alcoholic fatty liver disease in rats induced by high-fat diet combined with chronic stress. Chin J Gerontol. 40:177–181. 2020.In Chinese.

Cheng F, Ma C, Wang X, Zhai C, Wang G, Xu X, Mu J, Li C, Wang Z, Zhang X, et al: Effect of traditional Chinese medicine formula sinisan on chronic restraint stress-induced nonalcoholic fatty liver disease: A rat study. BMC Complement Altern Med. 17:2032017. View Article : Google Scholar : PubMed/NCBI

Cardoso A, Ferreira SC, Araújo MA, Mendes R, do Carmo LO, Moreira L, Ferreira L, Couto CA, Reis IA, Anastácio LR and Faria LC: Association between body composition, eating behavior, dietary intake, and metabolic dysfunction-associated steatotic liver disease in liver transplant recipients. Clin Nutr. 52:154–161. 2025. View Article : Google Scholar : PubMed/NCBI

Zhong Q, Zhou R, Huang YN, Huang RD, Li FR, Chen HW, Wei YF, Liu K, Cao BF, Liao KY, et al: Frailty and risk of metabolic dysfunction-associated steatotic liver disease and other chronic liver diseases. J Hepatol. 82:427–437. 2025. View Article : Google Scholar

Kineman RD, Del Rio-Moreno M and Waxman DJ: Liver-specific actions of GH and IGF1 that protect against MASLD. Nat Rev Endocrinol. 21:105–117. 2025. View Article : Google Scholar

Liu M, Zhang H, Niu M and Shen Y: Protective effects of decoction for strengthening spleen, tonifying qi, activating blood in rats with type 2 diabetes and non-alcoholic fatty liver disease. Mod J Integr Tradit Chin West Med. 31:3246–3251. 32682022.In Chinese.

Shi H: Effect of HYRG capsule on glucose and lipid metabolism-related enzymes oxidiation products in rats with qi and blood stasis type nonalcohlic fatty liver disease. Lanzhou: Gansu Univ Chin Med; 2019, In Chinese.

Chitturi S, Wong VW, Chan WK, Wong GL, Wong SK, Sollano J, Ni YH, Liu CJ, Lin YC, Lesmana LA, et al: The Asia pacific working party on non-alcoholic fatty liver disease guidelines 2017-Part 2: Management and special groups. J Gastroenterol Hepatol. 33:86–98. 2018. View Article : Google Scholar

Gjorgjieva M, Sobolewski C, Dolicka D, Correia de Sousa M and Foti M: MiRNAs and NAFLD: From pathophysiology to therapy. Gut. 68:2065–2079. 2019. View Article : Google Scholar : PubMed/NCBI

Hanin G, Yayon N, Tzur Y, Haviv R, Bennett ER, Udi S, Krishnamoorthy YR, Kotsiliti E, Zangen R, Efron B, et al: MiRNA-132 induces hepatic steatosis and hyperlipidaemia by synergistic multitarget suppression. Gut. 67:1124–1134. 2018. View Article : Google Scholar

Huang TT, Zhou YR, Zhang XJ and Liu SS: Advances in the treatment of nonalcoholic fatty liver disease. Med Rev. 21:1406–1409. 2015.In Chinese.

Liu JL and Li SH: Efficacy and safety of evolocumab and alirocumab in reducing lipids and cardiovascular events. J Evid-Based Med. 15:334–338. 2015.In Chinese.

Steffens D, Bramlage P, Scheeff C, Kasner M, Hassanein A, Friebel J and Rauch-Kröhnert U: PCSK9 inhibitors and cardiovascular outcomes. Expert Opin Biol Ther. 20:35–47. 2020. View Article : Google Scholar

Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Packard CJ, Bayes-Genis A, Cikes M, Fruchart GC, et al: 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 41:111–188. 2020. View Article : Google Scholar

Yerevanian A and Soukas AA: Metformin: Mechanisms in human obesity and weight loss. Curr Obes Rep. 8:156–164. 2019. View Article : Google Scholar : PubMed/NCBI

Cui H and Zhang X: Occurrence and clinical management of nonalcoholic fatty liver disease in obesity patients: A literature review. J Pediatr Endocrinol Metab. 33:579–584. 2020. View Article : Google Scholar : PubMed/NCBI

Adorini L, Pruzanski M and Shapiro D: Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis. Drug Discov Today. 17:988–997. 2012. View Article : Google Scholar : PubMed/NCBI

Mudaliar S, Henry RR, Sanyal AJ, Morrow L, Marschall HU, Kipnes M, Adorini L, Sciacca CI, Clopton P, Castelloe E, et al: Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology. 145:574–582.e1. 2013. View Article : Google Scholar : PubMed/NCBI

Sundelin EIO, Gormsen LC, Heebøll S, Vendelbo MH, Jakobsen S, Munk OL, Feddersen S, Brøsen K, Hamilton-Dutoit SJ, Pedersen SB, et al: Hepatic exposure of metformin in patients with non-alcoholic fatty liver disease. Br J Pharmacol. 85:1761–1770. 2019.

Knudsen LB and Lau J: The discovery and development of liraglutide and semaglutide. Front Endocrinol (Lausanne). 10:1552019. View Article : Google Scholar : PubMed/NCBI

López-Vicario C, González-Périz A, Rius B, Morán-Salvador E, García-Alonso V, Lozano JJ, Bataller R, Cofán M, Kang JX, Arroyo V, et al: Molecular interplay between Δ5/Δ6 desaturases and long-chain fatty acids in the pathogenesis of non-alcoholic steatohepatitis. Gut. 63:344–355. 2014. View Article : Google Scholar

Liu BB and Xu KS: Drug therapy for non-alcoholic fatty liver disease. Chin J Pract Intern Med. 39:214–217. 2019.In Chinese.

Abenavoli L, Falalyeyeva T, Boccuto L, Tsyryuk O and Kobyliak N: Obeticholic acid: A new era in the treatment of nonalcoholic fatty liver disease. Pharmaceuticals. 11:1042018. View Article : Google Scholar : PubMed/NCBI

Bell DSH and Jerkins T: In praise of pioglitazone: An economically efficacious therapy for type 2 diabetes and other manifestations of the metabolic syndrome. Diabetes Obes Metab. 25:3093–3102. 2023. View Article : Google Scholar : PubMed/NCBI

Sumida Y and Yoneda M: Current and future pharmacological therapies for NAFLD/NASH. J Gastroenterol. 53:362–376. 2018. View Article : Google Scholar :

Chen F, Fei X, Wang J, Shen Z, Liu W, Shao Z, Chen Y and Zhu Z: Effects of Qi-Ho expectorant formula on serum leptin and lipocalin in patients with non-alcoholic fatty liver disease. Lishizhen Med Mater Med Res. 26:843–844. 2015.In Chinese.

Lewis JD, Habel LA, Quesenberry CP, Strom BL, Peng T, Hedderson MM, Ehrlich SF, Mamtani R, Bilker W, Vaughn DJ, et al: Pioglitazone use and risk of bladder cancer and other common cancers in persons with diabetes. JAMA. 314:265–277. 2015. View Article : Google Scholar : PubMed/NCBI

Harrison SA, Alkhouri N, Davison BA, Sanyal A, Edwards C, Colca JR, Lee BH, Loomba R, Cusi K, Kolterman O, et al: Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double blind, placebo-controlled phase IIb study. J Hepatol. 72:613–626. 2020. View Article : Google Scholar

Chen Z, Tian R, She Z, Cai J and Li H: Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease. Free Radic Biol Med. 152:116–141. 2020. View Article : Google Scholar : PubMed/NCBI

Nagashimada M and Ota T: Role of vitamin E in nonalcoholic fatty liver disease. IUBMB Life. 71:516–522. 2019. View Article : Google Scholar

Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, Neuschwander-Tetri BA, Lavine JE, Tonascia J, Unalp A, et al: Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 362:1675–1685. 2010. View Article : Google Scholar : PubMed/NCBI

Lavine JE: Vitamin E treatment of nonalcoholic steatohepatitis in children: A pilot study. J Pediatr. 136:734–738. 2000. View Article : Google Scholar : PubMed/NCBI

Liu YL and Zhang QZ: An excerpt of the Asia-Pacific Working Party on nonalcoholic fatty liver disease guidelines 2017. J Clin Hepatol. 33:2278–2282. 2017.In Chinese.

Wah Kheong C, Nik Mustapha NR and Mahadeva S: A randomized trial of silymarin for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 15:1940–1949.e8. 2017. View Article : Google Scholar

Zhu X, Wu M, Wang H, Li H, Lin J, Peng Y, Hu Y, Li C and Ding Y: Safety, tolerability, and pharmacokinetics of the novel pan-phosphodiesterase inhibitor ZSP1601 in healthy subjects: A double-blinded, placebo-controlled first-in-human single-dose and multiple-dose escalation and food effect study. Expert Opin Investig Drugs. 30:579–589. 2021. View Article : Google Scholar : PubMed/NCBI

Hu Y, Li H, Zhang H, Chen X, Chen J, Xu Z, You H, Dong R, Peng Y, Li J, et al: ZSP1601, a novel pan-phosphodiesterase inhibitor for the treatment of NAFLD, A randomized, placebo-controlled phase Ib/IIa trial. Nat Commun. 14:64092023. View Article : Google Scholar : PubMed/NCBI

Xiang M, Wang PX, Wang AB, Zhang XJ, Zhang Y, Zhang P, Mei FH, Chen MH and Li H: Targeting hepatic TRAF1-ASK1 signaling to improve inflammation, insulin resistance, and hepatic steatosis. J Hepatol. 64:1365–1377. 2016. View Article : Google Scholar : PubMed/NCBI

Budas G, Karnik S, Jonnson T, Shafizadeh T, Watkins S, Breckenridge D and Tumas D: Reduction of liver steatosis and fibrosis with an ASK1 inhibitor in a murine model of NASH is accompanied by improvements in cholesterol, bile acid and lipid metabolism. J Hepatol. 64:S0702016. View Article : Google Scholar

Harrison SA, Wong VW, Okanoue T, Bzowej N, Vuppalanchi R, Younes Z, Kohli A, Sarin S, Caldwell SH, Alkhouri N, et al: Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials. J Hepatol. 73:26–39. 2020. View Article : Google Scholar : PubMed/NCBI

Lefere S, Devisscher L and Tacke F: Targeting CCR2/5 in the treatment of nonalcoholic steatohepatitis (NASH) and fibrosis: opportunities and challenges. Expert Opin Investig Drugs. 29:89–92. 2020. View Article : Google Scholar : PubMed/NCBI

Kruger AJ, Fuchs BC, Masia R, Holmes JA, Salloum S, Sojoodi M, Ferreira DS, Rutledge SM, Caravan P, Alatrakchi N, et al: Prolonged cenicriviroc therapy reduces hepatic fibrosis despite steatohepatitis in a diet-induced mouse model of nonalcoholic steatohepatitis. Hepatol Commun. 2:529–545. 2018. View Article : Google Scholar : PubMed/NCBI

Ratziu V, Sanyal A, Harrison SA, Wong VW, Francque S, Goodman Z, Aithal GP, Kowdley KV, Seyedkazemi S, Fischer L, et al: Cenicriviroc treatment for adults with nonalcoholic steatohepatitis and fibrosis: Final analysis of the phase 2b centaur study. Hepatology. 72:892–905. 2020. View Article : Google Scholar : PubMed/NCBI

Anstee QM, Neuschwander-Tetri BA, Wong VW, Abdelmalek MF, Younossi ZM, Yuan J, Pecoraro ML, Seyedkazemi S, Fischer L, Bedossa P, et al: Cenicriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: Aurora phase 3 study design. Contemp Clin Trials. 89:1059222020. View Article : Google Scholar

Pawlak M, Lefebvre P and Staels B: Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease. J Hepatol. 62:720–733. 2015. View Article : Google Scholar

Ratziu V, Harrison SA, Francque S, Bedossa P, Lehert P, Serfaty L, Romero-Gomez M, Boursier J, Abdelmalek M, Caldwell S, et al: Elafibranor, an agonist of the peroxisome proliferator-activated receptor-α and-δ, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening. Gastroenterology. 150:1147–1159.e5. 2016. View Article : Google Scholar

Wang J, Sun F, Yang JJ and Lu C: Effect of DNMT3A regulation of Drp1 on activated proliferation and migration capacity of hepatic stellate cells. Chin Pharmacol Bull. 38:1542–1547. 2022.In Chinese.

Chalasani N, Abdelmalek MF, Garcia-Tsao G, Vuppalanchi R, Alkhouri N, Rinella M, Noureddin M, Pyko M, Shiffman M, Sanyal A, et al: Effects of belapectin, an inhibitor of Galectin-3, in patients with nonalcoholic steatohepatitis with cirrhosis and portal hypertension. Gastroenterology. 158:1334–1345.e5. 2020. View Article : Google Scholar

Bi Z, Li G, Chen G, Yang Z, Long F, Luo L, Yang B and Tang D: Exploring the correlation between intestinal flora dysbiosis and hepatocellular carcinoma based on the theory of righteousness and evil in Chinese medicine. Mod J Integr Tradit Chin West Med. 31:1229–1234. 2022.In Chinese.

Said I, Ahad H and Said A: Gut microbiome in non-alcoholic fatty liver disease associated hepatocellular carcinoma: Current knowledge and potential for therapeutics. World J Gastrointest Oncol. 14:947–958. 2022. View Article : Google Scholar : PubMed/NCBI

Liu Q, Liu Y, Li F, Gu Z, Liu M, Shao T, Zhang L, Zhou G, Pan C, He L, et al: Probiotic culture supernatant improves metabolic function through FGF21-adiponectin pathway in mice. J Nutr Biochem. 75:1082562020. View Article : Google Scholar

Malaguarnera M, Vacante M, Antic T, Giordano M, Chisari G, Acquaviva R, Mastrojeni S, Malaguarnera G, Mistretta A, Li Volti G and Galvano F: Bifidobacterium longum with fructo-oligosaccharides in patients with nonalcoholic steatohepatitis. Dig Dis Sci. 57:545–553. 2012. View Article : Google Scholar

Wang H, Chen Q, Li H and Zhang Z: Adiponectin alleviates LPS-induced inflammatory response of microglia through A20/NLRP3/caspase-1 pathway. J Xi'an Jiaotong Univ (Med Sci). 42:529–533. 2021.In Chinese.

Fernandes P, Hashiguchi T, Fujii M and Yoneyama H: Anti-NASH effects of solithromycin in NASH-HCC mouse model. Gastroenterology. 146:145–146. 2014. View Article : Google Scholar

Kannt A, Wohlfart P, Madsen AN, Veidal SS, Feigh M and Schmoll D: Activation of thyroid hormone receptor-β improved disease activity and metabolism independent of body weight in a mouse model of non-alcoholic steatohepatitis and fibrosis. Br J Pharmacol. 178:2412–2423. 2021. View Article : Google Scholar : PubMed/NCBI

Mavromati M and Jornayvaz FR: Hypothyroidism-associated dyslipidemia: Potential molecular mechanisms leading to NAFLD. Int J Mol Sci. 22:127972021. View Article : Google Scholar : PubMed/NCBI

Hu L, Gu Y, Liang J, Ning M, Yang J, Zhang Y, Qu H, Yang Y, Leng Y and Zhou B: Discovery of highly potent and selective thyroid hormone receptor β agonists for the treatment of nonalcoholic steatohepatitis. J Med Chem. 66:3284–3300. 2023. View Article : Google Scholar : PubMed/NCBI

Karim G and Bansal MB: Resmetirom: An orally administered, small-molecule, liver-directed, β-selective THR agonist for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Touch Rev Endocrinol. 19:60–70. 2023.

Harrison SA, Bedossa P, Guy CD, Schattenberg JM, Loomba R, Taub R, Labriola D, Moussa SE, Neff GW, Rinella ME, et al: A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N Engl J Med. 390:497–509. 2024. View Article : Google Scholar : PubMed/NCBI

Loomba R, Neutel J, Mohseni R, Bernard D, Severance R, Dao M, Saini S, Margaritescu C, Homer K, Tran B, et al: VK2809, a novel liver-directed thyroid receptor beta agonist, significantly reduces liver fat with both low and high doses in patients with non-alcoholic fatty liver disease: A phase 2 randomized, placebo-controlled trial. J Hepatology. 70:e150–e151. 2019. View Article : Google Scholar

Leng YR, Zhang MH, Luo JG and Zhang H: Pathogenesis of NASH and promising natural products. Chin J Nat Med. 19:12–27. 2021.PubMed/NCBI

Chen M, Xie Y, Gong S, Wang Y, Yu H, Zhou T, Huang F, Guo X, Zhang H, Huang R, et al: Traditional Chinese medicine in the treatment of nonalcoholic steatohepatitis. Pharmacol Res. 172:1058492021. View Article : Google Scholar : PubMed/NCBI

Dai X, Feng J, Chen Y, Huang S, Shi X, Liu X and Sun Y: Traditional Chinese medicine in nonalcoholic fatty liver disease: molecular insights and therapeutic perspectives. Chin Med. 16:682021. View Article : Google Scholar : PubMed/NCBI

Deng Y, Liu H, Wu X, Cheng L, He M, Wang T and Ye L: Research progress on the hepatoprotective effects of polydatin. Chin J Comp Med. 31:136–140. 2021.In Chinese.

Pan L, Lv B, Jiang X, Wang T, Ma X, Chang N, Wang X and Gao X: Identification of NF-κB inhibitors following shenfu injection and bioactivity-integrated UPLC/Q-TOF-MS and screening for related anti-inflammatory targets in vitro and in silico. J Ethnopharmacol. 19:658–667. 2016.

Li L, Wang YL, Qin HY, Qu YY, Yang TS, Wang ZY and Xie JR: Research progress on berberine in treatment of nonalcoholic fatty liver disease by regulating gut-liver axis. Chin Tradit Herb Drugs. 52:1501–1509. 2021.In Chinese.

Liu YL, Zhang QZ, Wang YR, Fu LN, Han JS, Zhang J and Wang BM: Astragaloside IV Improves high-fat diet-induced hepatic steatosis in nonalcoholic fatty liver disease rats by regulating inflammatory factors level via TLR4/NF-κB signaling pathway. Front Pharmacol. 11:6050642020. View Article : Google Scholar

Zhao ZM, Wu JZ, Yao Z, Li YJ, Hou W, Chen WH and Shi AH: Effects of Cassia glycosides on the rats with non-alcoholic fatty liver disease through Toll-like receptor 4 and nuclear factor-κB. Chin J Clin Pharmacol. 35:2863–2867. 2019.In Chinese.

Paudel P, Jung HA and Choi JS: Anthraquinone and naphthopyrone glycosides from cassia obtusifolia seeds mediate hepatoprotection via Nrf2-mediated HO-1 activation and MAPK modulation. Arch Pharm Res. 41:677–689. 2018. View Article : Google Scholar : PubMed/NCBI

Zhang Y, Cheng S, Zhou F, Zhang L, Su Z, Zhao D, Chen Y and Jia Y: Effects of geniposide on inflammation and oxidative stress of ApoE knockout mice with atherosclerosis and none-alcoholic fatty liver disease. Tradit Chin Drug Res Clin Pharmacol. 26:581–586. 2015.In Chinese.

Lee JH, Jung IR, Choi SE, Lee SM, Lee SJ, Han SJ, Kim HJ, Kim DJ, Lee KW and Kang Y: Toxicity generated through inhibition of pyruvate carboxylase and carnitine palmitoyl transferase-1 is similar to high glucose/palmitate-induced glucolipotoxicity in INS-1 beta cells. Mol Cell Endocrinol. 383:48–59. 2014. View Article : Google Scholar

Xu QM, Gao Y, Li ZM, Wei RM, Ma XH, Jin L and Zhang KF: The effect of gentiopicroside on TLR-4/NF-κB and AMPK/Nrf2 in non-alcoholic fatty liver disease. Nat Prod Res Dev. 32:1652–1658. 2020.In Chinese.

Molteni M, Gemma S and Rossetti C: The role of toll-like receptor 4 in infectious and noninfectious inflammation. Mediators Inflamm. 2016:69789362016. View Article : Google Scholar : PubMed/NCBI

Wang QB, Xu FP, Wei CX, Peng J and Dong XD: Research progress on free radicals in the human body. Zhonghua Liu Xing Bing Xue Za Zhi. 37:1175–1182. 2016.In Chinese. PubMed/NCBI

Huang Z, Wei Y, Wang Z, Lai PL, Zeng BH, Xu JJ and Yang YL: Effects of total glucosides paeony on TLR4 and JNK protein expression in inflammatory pathway of NAFLD rats. J Hunan Normal Univ (Med Sci). 15:23–27. 2018.In Chinese.

Shen S, Wang K, Zhi Y, Shen W and Huang L: Gypenosides improves nonalcoholic fatty liver disease induced by high-fat diet induced through regulating LPS/TLR4 signaling pathway. Cell Cycle. 19:3042–3053. 2020. View Article : Google Scholar : PubMed/NCBI

Li X, Fang C, Xu Y, Xu B and Zheng X: Effect of hesperidin on CYP2E1 expression in nonalcoholic fatty liver rats induced by high fructose diet. Mod J Integr Tradit Chin West Med. 29:2635–2639. 2020.In Chinese.

Park S, Choi Y, Um SJ, Yoon SK and Park T: Oleuropein attenuates hepatic steatosis induced by high-fat diet in mice. J Hepatol. 54:984–993. 2011. View Article : Google Scholar

Chen M, Liu G, Fang Z, Gao W, Song Y, Lei L, Du X and Li X: Buddleoside alleviates nonalcoholic steatohepatitis by targeting the AMPK-TFEB signaling pathway. Autophagy. 21:1316–1334. 2025. View Article : Google Scholar : PubMed/NCBI

Yin Y, Liu H, Zheng Z, Lu R and Jiang Z: Genistein can ameliorate hepatic inflammatory reaction in nonalcoholic steatohepatitis rats. Biomed Pharmacother. 111:1290–1296. 2019. View Article : Google Scholar : PubMed/NCBI

Liu X, Sun R, Li Z, Lv P, Sun X, Olson MA and Gong Y: Luteolin alleviates non-alcoholic fatty liver disease in rats via restoration of intestinal mucosal barrier damage and microbiota imbalance involving in gut-liver axis. Arch Biochem Biophys. 711:1090192021. View Article : Google Scholar : PubMed/NCBI

Kou X, Hong M, Pan F, Huang X, Meng Q, Zhang Y and Ke Q: Inhibitory effects of nobiletin-mediated interfacial instability of bile salt emulsified oil droplets on lipid digestion. Food Chem. 444:1387512024. View Article : Google Scholar : PubMed/NCBI

He TT, Qian YL and Chen WM: Study on constitution classification of TCM for 260 nonalcoholic fatty liver disease patients. Inner Mong J Tradit Chin Med. 37:1–2. 2018.In Chinese.

Pan YT, Xu FY, Yu XZ and Shang WB: Research progress on therapeutic targets of active components in Chinese herbs for treatment of nonalcoholic fatty liver disease. Zhongguo Zhong Yao Za Zhi. 42:1109–1112. 2017.In Chinese. PubMed/NCBI

Liang ZQ, Bai JH, Zhao RH, Liu YH, Li LM and Lin QX: Effect of ginkgo flavone on nonalcoholic fatty liver disease in mice and the correlation analysis on NF-κB in the action mechanism. Nat Prod Res Dev. 28:277–282. 2016.In Chinese.

Huang L, Ding W, Wang MQ, Wang ZG, Chen HH, Chen W, Yang Q, Lu TN, Yang Q and He JM: Tanshinone IIA ameliorates non-alcoholic fatty liver disease through targeting peroxisome proliferator-activated receptor gamma and toll-like receptor 4. J Int Med Res. 47:5239–5255. 2019. View Article : Google Scholar : PubMed/NCBI

Zheng Y, Wang J, Wang J, Xie H and Zhao T: Effect of curcumol on the fenestrae of liver sinusoidal endothelial cells based on NF-κB signaling pathway. Evid Based Complement Alternat Med. 2020:85906382020. View Article : Google Scholar

Han LP, Sun B, Li CJ, Xie Y and Chen LM: Effect of celastrol on toll-like receptor 4-mediated inflammatory response in free fatty acid-induced HepG2 cells. Int J Mol Med. 42:2053–2061. 2018.PubMed/NCBI

Ye Z, Zhu K, He Y, Chen L and Zhang J: Mechanism of asiatic acid improving nonalcoholic fatty liver disease by regulating TLR4/NF-κB/NLRP3 signaling pathway. China Food Addit. 35:201–207. 2024.In Chinese.

Malekinejad H, Zeynali-Moghaddam S, Rezaei-Golmisheh A, Alenabi A, Malekinejad F, Alizadeh A and Shafie-Irannejad V: Lupeol attenuated the NAFLD and PCOS-induced metabolic, oxidative, hormonal, histopathological, and molecular injuries in mice. Res Pharm Sci. 18:551–565. 2023. View Article : Google Scholar : PubMed/NCBI

Brusotti G, Montanari R, Capelli D, Cattaneo G, Laghezza A, Tortorella P, Loiodice F, Peiretti F, Bonardo B, Paiardini A, et al: Betulinic acid is a PPARγ antagonist that improves glucose uptake, promotes osteogenesis and inhibits adipogenesis. Sci Rep. 7:57772017. View Article : Google Scholar

Hou L and Xiao Y: Study on the distribution of Chinese medicine evidence elements in non-alcoholic fatty liver disease. Mod J Integr Tradit Chin West Med. 24:2116–2118. 2015.In Chinese.

Zhang L, Zhao Y, Li Z, Guo D and Fu S: Correlative study between ultrasonic echo intensity parameters and Traditional Chinese Medicine syndromes of fatty liver. Chin J Ultrasound Med. 28:55–58. 2012.In Chinese.

He F, Zhang X and Wen X: Effects of crataegolic acid on inflammatory response and oxidative stress in non-alcoholic fatty liver disease model mice induced by high-fat diet. China Pharm. 30:901–905. 2019.In Chinese.

Zhou X, Ren Q, Wang B, Fang G, Ling Y and Li X: Alisol A 24-Acetate Isolated from the alismatis rhizoma improves hepatic lipid deposition in hyperlipidemic mice by ABCA1/ABCG1 pathway. J Nanosci Nanotechnol. 19:5496–5502. 2019. View Article : Google Scholar : PubMed/NCBI

Ho C, Gao Y, Zheng D, Liu Y, Shan S, Fang B, Zhao Y, Song D, Zhang Y and Li Q: Alisol A attenuates high-fat-diet-induced obesity and metabolic disorders via the AMPK/ACC/SREBP1c pathway. J Cell Mol Med. 23:5108–5118. 2019. View Article : Google Scholar : PubMed/NCBI

Li X, Chen XX, Xu Y, Xu XB, Wu WF, Zhao Q and Hu JN: Construction of Glycogen-Based Nanoparticles loaded with resveratrol for the alleviation of high-fat diet-induced nonalcoholic fatty liver disease. Biomacromolecules. 23:409–423. 2022. View Article : Google Scholar

Feng D, Zou J, Su D, Mai H, Zhang S, Li P and Zheng X: Curcumin prevents high-fat diet-induced hepatic steatosis in ApoE^−/− mice by improving intestinal barrier function and reducing endotoxin and liver TLR4/NF-κB inflammation. Nutr Metab (Lond). 16:792019. View Article : Google Scholar

Zhang M, Zhang Y, Tang L, Gong Z, Han L and Wang D: Gastrodin inhibits non-alcoholic fatty liver disease via mediating SREBP1c signaling pathway. Chin J Exp Tradit Med Formul. 30:70–77. 2024.In Chinese.

Xiao J, Zhang R, Zhou Q, Liu L, Huang F, Deng Y, Ma Y, Wei Z, Tang X and Zhang M: Lychee (litchi chinensis sonn.) pulp phenolic extract provides protection against alcoholic liver injury in mice by alleviating intestinal microbiota dysbiosis, intestinal barrier dysfunction and liver inflammation. J Agric Food Chem. 65:9675–9684. 2017. View Article : Google Scholar : PubMed/NCBI

Aithal GP, Thomas JA, Kaye PV, Lawson A, Ryder SD, Spendlove I, Austin AS, Freeman JG, Morgan L and Webber J: Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology. 135:1176–1184. 2008. View Article : Google Scholar : PubMed/NCBI

Castellino G, Nikolic D, Magán-Fernández A, Malfa GA, Chianetta R, Patti AM, Amato A, Montalto G, Toth PP, Banach M, Cicero AFG and Rizzo M: Altilix® supplement containing chlorogenic acid and luteolin improved hepatic and cardiometabolic parameters in subjects with metabolic syndrome: A 6 month randomized, double-blind, placebo-controlled study. Nutrients. 11:25802019. View Article : Google Scholar

Tan Y, Kim J, Cheng J, Ong M, Lao WG, Jin XL, Lin YG, Xiao L, Zhu XQ and Qu XQ: Green tea polyphenols ameliorate non-alcoholic fatty liver disease through upregulating AMPK activation in high fat fed Zucker fatty rats. World J Gastroenterol. 23:3805–3814. 2017. View Article : Google Scholar : PubMed/NCBI

Chen X, Ren Y, Kong W and Wang Y: Effect of salvianolic acid B on oxidative stress in a cell model of nonalcoholic fatty liver disease. J Clin Hepatol. 34:2175–2181. 2018.In Chinese.

Zhang X, Li T, Liu S, Wu Q, Lin Z, Pan Y and Alitongbieke G: Mechanism of berberine improving non-alcoholic fatty liver induced by high-fat diet in mice. Chin J Bioprocess Eng. 19:657–661. 2021.In Chinese.

Kim R, Kim SB, Cho EH, Park SH, Park SB, Hong SK and Chae G: CD44 expression in patients with combined hepatocellular cholangiocarcinoma. Ann Surg Treat Res. 89:9–16. 2015. View Article : Google Scholar : PubMed/NCBI

Sun T, Xue M, Yang J, Pei Z, Zhang N, Qin K and Liang H: Metabolic regulation mechanism of fucoidan via intestinal microecology in diseases. J Sci Food Agric. 101:4456–4463. 2021. View Article : Google Scholar : PubMed/NCBI

Cani PD and Delzenne NM: The role of the gut microbiota in energy metabolism and metabolic disease. Curr Pharm Des. 15:1546–1558. 2009. View Article : Google Scholar : PubMed/NCBI

Zhang DD, Zhang JG, Wang YZ, Liu Y, Liu GL and Li XY: Per-Arnt-Sim kinase (PASK): An emerging regulator of mammalian glucose and lipid metabolism. Nutrients. 7:7437–7450. 2015. View Article : Google Scholar : PubMed/NCBI

Rahban M, Zolghadri S, Salehi N, Ahmad F, Haertlé T, Rezaei-Ghaleh N, Sawyer L and Saboury AA: Thermal stability enhancement: fundamental concepts of protein engineering strategies to manipulate the flexible structure. Int J Biol Macromol. 214:642–644. 2022. View Article : Google Scholar : PubMed/NCBI

Zhong M, Yan Y, Yuan H, A R, Xu G, Cai F, Yang Y, Wang Y and Zhang W: Astragalus mongholicus polysaccharides ameliorate hepatic lipid accumulation and inflammation as well as modulate gut microbiota in NAFLD rats. Food Funct. 13:7287–7301. 2022. View Article : Google Scholar : PubMed/NCBI

Wang L, Li W, Li Y, Chen G, Zhao L, Li W, Wang S, Wang C, Feng Y and Zhang Y: Dried tangerine peel polysaccharide (DTPP) alleviates hepatic steatosis by suppressing TLR4/MD-2-mediated inflammation and endoplasmic reticulum stress. Bioorg Chem. 147:1073692024. View Article : Google Scholar : PubMed/NCBI

Yu J, Fan Y, Yang Y, He D, Song B and Yao Z: Influence of dendrobium nobile polysaccharide on the expression of TLR4 and HO-1 in rats with nonalcoholic fatty liver disease. West J Tradit Chin Med. 34:25–29. 2021.In Chinese.

Liu HP, Zhang RJ, Cao HK, Gao Y and Wang YW: Study on effects of Polygala fallax polysaccharide on nonalcoholic fatty liver in rats by PPAR-γ and TLR-4/NF-κB signaling pathway. J Chin Med Mater. 47:1247–1252. 2024.In Chinese.

Zhang K and Jin L: Protective effect and mechanism of dicliptera chinensis polysaccharides on non-alcoholic fatty liver disease in rats based on PPAR-γ and TLR-4/NF-κB signaling pathway. Pharmacol Clin Chin Mater Med. 35:103–107. 2019.In Chinese.

Zhao H, Gao X, Liu Z, Zhang L, Fang X, Sun J, Zhang Z and Sun Y: Sodium alginate prevents non-alcoholic fatty liver disease by modulating the gut-liver axis in high-fat diet-fed rats. Nutrients. 14:48462022. View Article : Google Scholar : PubMed/NCBI

Liu X, Su J, Shi Y, Guo Y, Suheryani I, Zhao S, Deng Y, Meng W, Chen Y, Sun L and Dai R: Herbal Formula, Baogan Yihao (BGYH), prevented dimethylnitrosamine(DMN)-indu ced liver injury in rats. Drug Dev Res. 78:155–163. 2017. View Article : Google Scholar : PubMed/NCBI

Xie R, Lin D, Yang L and Li F: Protective effect and mechanism of zingerone on rats with nonalcoholic fatty liver disease. J Shenyang Pharm Univ. 39:684–689. 2022.In Chinese.

Lv YL, Liu CC, Liu H, Xu KY, Qiao L and Bao JF: Effects of rhein on TLR4 signaling pathway in NAFLD rats. Chin J Health Lab Tec. 28:2580–2584. 2018.In Chinese.

Wei J, Zhen YZ, Cui J, He FL, Shen T, Hu G, Ren XH and Lin YJ: Rhein lysinate decreases inflammation and adipose infiltration in KK/HlJ diabetic mice with nonalcoholic fatty liver disease. Arch Pharm Res. 39:960–969. 2016. View Article : Google Scholar : PubMed/NCBI

Dong X, Fu J, Yin X, Cao S, Li X, Lin L, Huyiligeqi and Ni J: Emodin: a review of its pharmacology, toxicity and pharmacokinetics. Phytother Res. 30:1207–1218. 2016. View Article : Google Scholar : PubMed/NCBI

Ye J, Zheng J, Tian X, Xu B, Yuan F, Wang B, Yang Z and Huang F: Fucoxanthin attenuates free fatty acid-induced nonalcoholic fatty liver disease by regulating lipid metabolism/oxidative stress/inflammation via the AMPK/Nrf2/TLR4 signaling pathway. Mar Drugs. 20:2252022. View Article : Google Scholar : PubMed/NCBI

Borstlap WAA, Musters GD, Stassen LPS, van Westreenen HL, Hess D, van Dieren S, Festen S, van der Zaag EJ, Tanis PJ and Bemelman WA: Vacuum-assisted early transanal closure of leaking low colorectal anastomoses: The CLEAN study. Surg Endosc. 32:315–327. 2018. View Article : Google Scholar :

Yu S, Jiang J, Li Q, Liu X, Wang Z, Yang L and Ding L: Schisantherin a alleviates non-alcoholic fatty liver disease by restoring intestinal barrier function. Front Cell Infect Microbiol. 12:8550082022. View Article : Google Scholar : PubMed/NCBI

Gu L, Zhang Y, Zhang S, Zhao H, Wang Y, Kan D, Zhang Y, Guo L, Lv J, Hao Q, et al: Coix lacryma-jobi seed oil reduces fat accumulation in nonalcoholic fatty liver disease by inhibiting the activation of the p-AMPK/SePP1/apoER2 pathway. J Oleo Sci. 70:685–696. 2021. View Article : Google Scholar : PubMed/NCBI

Pan MX, Zheng CY, Deng YJ, Tang KR, Nie H, Xie JQ, Liu DD, Tu GF, Yang QH and Zhang YP: Hepatic protective effects of shenling baizhu powder, a herbal compound, against inflammatory damage via TLR4/NLRP3 signalling pathway in rats with nonalcoholic fatty liver disease. J Integr Med. 19:428–438. 2021. View Article : Google Scholar : PubMed/NCBI

Du N, Yang J, Xu D, Zhang S and Shi Z: Fuzi Lizhong decoction modulates bile acid metabolism in nonalcoholic fatty liver disease viathe FXR-FGF15 signaling pathway. Med J West China. 36:1576–1581. 2024.In Chinese.

Liu H, Xu J, Li H, Zhang L and Xu P: Network pharmacology-based investigation to explore the effect and mechanism of erchen decoction against the nonalcoholic fatty liver disease. Anat Rec (Hoboken). 304:2605–2619. 2021. View Article : Google Scholar : PubMed/NCBI

Zhang Y, Zhou G, Chen Z, Guan W, Zhang J, Bi M, Wang F, You X, Liao Y, Zheng S, et al: Si-Wu-Tang alleviates nonalcoholic fatty liver disease via blocking tlr4-jnk and caspase-8-gsdmd signaling pathways. Evid Based Complement Alternat Med. 2020:87864242020. View Article : Google Scholar : PubMed/NCBI

Su L, Lin J, Liu X, Ye X and Chen J: Clinical study on Xiaoyao San prescription combined with silymarin capsules for non-alcoholic fatty liver disease with syndrome of liver depression and spleen deficiency. New Chin Med. 56:42–46. 2024.In Chinese.

Feng W, Su A, Huang X and Wang C: Mechanism of Huangqisan regulating autophagy by AMPK/mTOR signaling pathway against hepatic steatosis. Chin J Exp Tradit Med Formul. 29:21–30. 2023.In Chinese.

Xia M, Zhang Z, Shen H and Kang J: Study on clinical regression of non-alcoholic fatty liver disease by nourishing yin and softening liver method. J New Chin Med. 48:52–54. 2016.In Chinese.

Lu S, Lu S, Chen Y, Shen T and Li Y: Qinghua formula for the treatment of non-alcoholic fatty liver disease with phlegm internal obstruction type: A clinical study. World Sci Technol - Mod Tradit Chin Med. 21:1759–1765. 2019.In Chinese.

Xie WN, Peng HB and Li Y, Huang LP, Chen SX, Wu YF and Li Y: Liver with liver stagnation and spleen deficiency syndrome and intestinal microflora. Chin J Exp Tradit Med Formul. 27:129–137. 2021.In Chinese.

Xu L, Fu J, Fang F, Chen LZ and Zhuang GF: Effect of modfied Yinchen Wuling San in treating non-alcoholic fatty liver disease with moisture and heat implication and on intestinal microflora. Chin J Exp Tradit Med Formul. 25:127–132. 2019.In Chinese.

Zhan YH, Wang XH and Wang F: Regulatory effect of modified Banxia Xiexintang on insulin resistance of patients with nonalcoholic fatty liver. Chin J Exp Tradit Med Formul. 27:117–122. 2021.In Chinese.

Wan Y, Zhang Z, Song G and Ouyang J: Clinical effect of Yishen Tiaogan recipe combined with probiotics on nonalcoholic fatty liver disease. Chin Arch Tradit Chin Med. 38:10–13. 2020.In Chinese.

Chen L, Huang Q, Liu S and Lu Z: Clinical observation of Wuling powder combined with polyene phosphatidylcholine on patients with nonalcoholic fatty liver disease. Chin Arch Tradit Chin Med. 38:190–193. 2020.In Chinese.

Mian F and Yang R: Study on the effects of activating blood and eliminating lipids formula on TNF-α, TGF and FFA in patients with non-alcoholic fatty liver disease. World Latest Med Inf. 18:136–137. 2018.In Chinese.

Zhang Y, Ni Y, Zhang J, Li J and Liu H: Effectiveness of spleen-strengthening and fat-eliminating formula in treating patients with type 2 diabetes mellitus combined with nonalcoholic fatty liver disease and its effect on HMGB1 and TLR4 levels. Lishizhen Med Mater Med Res. 35:261–264. 2024.In Chinese.

Wang S, Ning M, Wang Y, Yang X and Li M: Study on the therapeutic effect and mechanism of anemarrhenae-hawthorn drink on non-alcoholic fatty liver in rats. Anhui Med Pharm J. 27:1927–1932. 2023.In Chinese.

Wang S, Xu WX, Shen MY, Li C, La XJ, Li JA, Qi YJ, Wang XP and Wu Z: Effect of Tongping Zhigan formula on liver tissue inflammation and TLR4/MyD88/NF-κB pathway in non-alcoholic fatty liver mice. J Hebei Tradit Chin Med Pharmacol. 39:1–6. 2024.In Chinese.

Ding Y, Ou X, Li C, Li X and Lian S: An investigation of the mechanism of Qinggan Jiangzhuo particles in the treatment of nonalcoholic fatty liver disease based on the TLR4/NF-κB signaling pathway. Jilin J Chin Med. 41:1489–1492. 2021.In Chinese.

Chen Z, Xiang S, Yang M, Xia F and Zhou B: Study on the molecular mechanism of liver-protecting and lipid-cleansing tablets for the treatment of non-alcoholic fatty liver disease based on network pharmacology. J Chin Med Mater. 43:1462–1468. 2020.In Chinese.

Ye M, Xue J, Li F, Yang Y, He J and Tang Y: Study on regulation and mechanism of Huazhi Fugan granules on TLR4/NF-κB pathway and fatty iron death in non-alcoholic fatty liver. Mod J Integr Tradit Chin West Med. 30:3307–3312. 2021.In Chinese.

Guo HH, Shen HR, Zhang HJ, Wang LL, Han YX and Jiang JD: Dengzhan shengmai inhibits nonalcoholic fatty liver disease via regulating intestinal microenvironment. Acta Pharm Sin. 57:3524–3534. 2022.In Chinese.

Liao Y, Chi X, Yang Y, Wu Y, Zhan Y and Song Y: Effects of Zhibitai on the expressions of ERK and TLRs in liver tissues of NAFLD rats. Pharmacol Clin Chin Mater Med. 35:130–134. 2019.In Chinese.

Yang JF, Xue JB, Tao YY, Huang K, Lu J and Liu CH: Mechanism of Kuhuang Granules in treating non-alcoholic fatty liver disease based on network pharmacology and experimental validation. J Integr Tradit Chin West Med Hepatol. 32:58–62. 2022.In Chinese.

Winn NC, Liu Y, Rector RS, Parks EJ, Ibdah JA and Kanaley JA: Energy-matched moderate and high intensity exercise training improves nonalcoholic fatty liver disease risk independent of changes in body mass or abdominal adiposity-a-randomized trial. Metabolism. 78:128–140. 2018. View Article : Google Scholar

Hannah WN Jr and Harrison SA: Lifestyle and dietary interventions in the management of nonalcoholic fatty liver disease. Dig Dis Sci. 61:1365–1374. 2016. View Article : Google Scholar : PubMed/NCBI

Fogacci F, Rizzoli E, Giovannini M, Bove M, D'Addato S, Borghi C and Cicero AFG: Effect of dietary supplementation with eufortyn colesterolo plus on serum lipids, endothelial reactivity, indexes of non-alcoholic fatty liver disease and systemic inflammation in healthy subjects with polygenic hypercholesterolemia: The ANEMONE study. Nutrients. 14:20992022. View Article : Google Scholar

Fatemeh H, Abdollah H, Bizhan H, Seyed-Saeed S and Kambiz AA: An energy-restricted high-protein diet supplemented with beta-cryptoxanthin alleviated oxidative stress and inflammation in nonalcoholic fatty liver disease: A randomized controlled trial. Nutr Res. 73:15–26. 2020. View Article : Google Scholar

Yang M, Xue J, Li F, Dong L and Fu Q: Effect of Chinese medicine starvation-free fasting therapy on glucolipid metabolism and liver fat deposition in patients with nonalcoholic fatty liver disease. China Med Herald. 17:135–138. 2020.In Chinese.

Yang R, Wan L, Zhu H and Peng Y: The effect of 12 week-maximum fat oxidation intensity (FATmax) exercise on microvascular function in obese patients with nonalcoholic fatty liver disease and its mechanism. Gen Physiol Biophys. 42:251–262. 2023. View Article : Google Scholar : PubMed/NCBI

Li H, Sun P, Chen Y and Jia H: Research on the intervention of NAFLD by Baduanjin. J Chengdu Sport Univ. 44:79–83. 902018.In Chinese.

Vahedi H, Atefi M, Entezari MH and Hassanzadeh A: The effect of sesame oil consumption compared to sunflower oil on lipid profile, blood pressure, and anthropometric indices in women with non-alcoholic fatty liver disease: A randomized double-blind controlled trial. Trials. 23:5512022. View Article : Google Scholar : PubMed/NCBI

Guo W, Li Z, Anagnostopoulos G, Kong WT, Zhang S, Chakarov S, Shin A, Qian J, Zhu Y, Bai W, et al: Notch signaling regulates macrophage-mediated inflammation in metabolic dysfunction-associated steatotic liver disease. Immunity. 57:2310–2327.e6. 2024. View Article : Google Scholar : PubMed/NCBI

Palomer X, Wang JR, Escalona C, Wu S, Wahli W and Vázquez-Carrera M: Targeting AMPK as a potential treatment for hepatic fibrosis in MASLD. Trends Pharmacol Sci. 46:551–566. 2025. View Article : Google Scholar : PubMed/NCBI

Nóvoa E, da Silva Lima N, Gonzalez-Rellan MJ, Chantada-Vazquez MDP, Verheij J, Rodriguez A, Esquinas-Roman EM, Fondevila MF, Koning M, Fernandez U, et al: Mitochondrial antiviral signaling protein enhances MASLD progression through the ERK/TNFα/NFκβ pathway. Hepatology. 81:1535–1552. 2025. View Article : Google Scholar

Yu Y, Wang Q, Huang X and Li Z: GA receptor targeted chitosan oligosaccharide polymer nanoparticles improve non-alcoholic fatty liver disease by inhibiting ferroptosis. Int J Biol Macromol. 278:1347792024. View Article : Google Scholar : PubMed/NCBI